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While the current gold standard, BCG is highly effective as an adjuvant to surgery 
in treating superficial bladder cancer, it is nevertheless associated with debilitating side-
effects. The need for alternatives is thus pertinent.   
Clinical trials with oral Lactobacillus preparations have proven well tolerated and 
largely free of adverse effects, hence providing a strong rationale for evaluating 
intervention strategies for LGG in bladder cancer models. Using healthy C57BL/6 mice, 
it was shown that live whole LGG was safe for use as an intravesical immunotherapeutic 
agent – no host morbidities or mortalities were recorded as a result of live LGG use. 
However, live LGG’s immunogenicity was poor compared to live BCG. The latter was 
found to upregulate cytokine and chemokine mRNA transcripts, and simultaneously 
recruiting more macrophages to the bladder within 5 instillations.   
To augment LGG’s immunogenicity, LGG was lyophilised since lyophilised 
biologicals are known to contain highly immunostimulatory cellular debris, and as such 
are better than whole live bacteria in triggering an immune response. It was subsequently 
found that lyophilised LGG (lyo LGG) was more effective than live LGG in inducing 
IL10, TNFα and IL12p40 production in splenocytes. It was also able to significantly 
upregulate more cytokine and chemokine expression when instilled in a healthy mouse 
host. At the same time, lyo LGG was found to attract activated and mature dendritic cells 
to the bladder.  
Following this, LGG’s efficacy as an adjuvant in bladder cancer therapy was 
tested. Using the poly-L-lysine-induced murine orthotopic bladder cancer model, live and 
lyo LGG therapy was found to confer a 30% survival advantage over controls (p < 0.05). 
  
xvii
Oral feeding of live LGG in addition to lyo LGG instillations, did not augment lyo 
LGG’s anti-tumour efficiency. The mice were typically cured of bladder tumour between 
the 2nd and 3rd instillations. 
Lyo LGG instillations led to massive numbers of neutrophils and some 
macrophages infiltrating the tumour from as early as after the 2nd instillation. It was 
found that LGG therapy could influence both local and systemic immune responses as 
marked by the changes in Ly6G+, Mac-3+ and CD3+CD8+ cell populations in the local 
lymph nodes and spleen. To confirm the treatment protocol was as efficacious as 
Immucyst, a further set of experiments were performed to compare the cure rates between 
Immucyst and lyo LGG. Lyo LGG, but not Immucyst significantly upregulated TNFα 
expression in the local lymph nodes, indicating that TNFα may be essential in mediating 
anti-tumour responses.  
In vitro experiments to further elucidate LGG’s anti-tumour mechanisms found 
that only living but not heat-killed LGG can induce cytotoxicity. Both live and lyo LGG 
induced a significant accumulation of cells in the sub-G1 phase in a time-dependent 
manner with cells showing necrotic characteristics and no observable caspase-3 activity. 
















1.1 Bladder Cancer – An Overview 
Bladder cancer accounts for approximately 5% of all cancer deaths in man. While 
the World Health Organisation ranks bladder cancer as the 10th most common cancer in 
the male gender, it is the 2nd most common form of genitourinary cancer to inflict men. In 
Singapore, bladder cancer accounted for about 2% of all cancer deaths in males between 
the years 1998 and 2002 [1].  
Although the causes of bladder cancer are not yet fully understood, various 
lifestyle, biological and environmental risk factors have been identified. Cigarette 
smoking may account for over 50% of cases in men and 35% in women [2]; being older, 
male or Caucasian also increase the risk of cancer; so does a diet high in fried meats and 
fat [3]. Persistent bladder inflammation such as urinary stones [4] or Schistosomiasis [5] 
also increases the risks of cancer. Chronic exposure to chemicals used in hairdressing 
supplies [6, 7], rubber, textile and paint industries lead to high levels of carcinogens (e.g. 
aromatic amines) in urine [8], which may in turn lead to mutagenesis and eventually 
bladder cancer induction. 
The majority of bladder tumours (70 – 80%) are superficial, non-muscle invasive 
tumours at the point of diagnosis. It is a characteristic of bladder cancer that despite 
successful initial treatment, the local recurrence rate is high (70%) [9]; of these 20–30% 
progress to a higher stage cancer [10]. As a result, patients often require long 
maintenance and surveillance programmes. Table 1.1 describes and defines the various 





Table 1.1 Stages of superficial bladder cancer  
Stage Description 
 
Ta Papillary, mucosally confined, basement membrane intact 
 
Tis  
(Carcinoma in situ 
[Cis]) 
“Flat,” full-thickness mucosal involvement with high-grade cells, 
diffuse or focal bladder involvement 
 
T1 Invades lamina propria, muscularis propria not involved 
 
T2 Tumour invades muscle 
 
pT2a Tumour invades superficial muscle (inner half) 
 
pT2b Tumour invades deep muscle (outer half) 
 




pT3b Macroscopically (extravesical mass) 
 
T4 Tumour invades any of the following: prostate, uterus, vagina, 
pelvic wall or abdominal wall 
 
T4a Tumour invades prostate, uterus, vagina 
 
T4b Tumour invades pelvic wall, abdominal wall 
 
 
1.2 Bladder cancer therapy 
1.2.1 Surgery 
Transurethral resection (TUR) of the tumour is the primary treatment for Ta and 
T1 bladder cancer. However because of the high recurrence rate and the unpredictability 
of disease progression, post-surgery adjuvant therapies such as chemotherapy, 





1.2.2 Intravesical chemotherapeutic agents 
Thiotepa (N,N'N'-triethylenethiophosphoramide), Doxorubin, Epirubicin and 
Mitomycin C (MMC) are some of the intravesical chemotherapeutic agents that are 
administered. The average recurrence rates for Thiotepa and Doxorubin adjuvant 
chemotherapy treatments following TUR are 61% and 58% respectively [12]. While 
existing chemotherapeutic agents are comparable in efficacy, they differ in toxicity; 
furthermore, there is no universal protocol for drug administration.  
 
1.2.3 Bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer  
BCG is an attenuated strain of Mycobacterium bovis which was developed by 
Calmette and Guerin with the intention of generating a vaccine against tuberculosis. Pearl 
published his observations that patients with tuberculosis rarely developed malignant 
neoplasms [13]. Based on this and other observations, Morales et al investigated a new 
application for BCG. In 1976, they developed a schedule for the effective adjuvant 
intravesical therapy of non-muscle invasive bladder cancer following TUR [14]. BCG 
immunotherapy is presently the gold standard for treating superficial bladder cancer.  
Intravesical BCG immunotherapy after TUR is superior to TUR alone as shown 
by Sylvester et al [15]. TUR with intravesical BCG immunotherapy has also been shown 
to be more efficacious than chemotherapy in patients with high risk for cancer recurrence.  
BCG immunotherapy results in complete response in half or more of patients with 
papillary tumours. In patients with bladder carcinoma in situ (CIS), the complete 
response rate is more than 70% [16]. There are at least 5 commonly used BCG strains - 
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Tice, Pasteur, Connaught, RIVM and Armand Frappier and they do not differ in their 
ability to prevent tumour progression [15].  
 
1.2.4 ImmuCyst® [Bacillus Calmette-Guérin (BCG), substrain Connaught]  
ImmuCyst® is a freeze-dried preparation made from the Connaught substrain of 
Bacillus Calmette-Guérin (an attenuated strain of Mycobacterium bovis). Intravesical 
ImmuCyst® has been studied and established as both an alternative to radical surgical 
treatment for CIS and as prophylaxis for recurrence of CIS. Intravesical BCG therapy 
usually begins 7 - 14 days after biopsy or TUR. It consists of an induction and a 
maintenance schedule. The former comprises 1 intravesical instillation of ImmuCyst® 
per week for 6 weeks. This is followed by 6 weeks of no-treatment, and then the 
maintenance therapy of 1 intravesical dose per week for 1 - 3 weeks [17].  
Treatment of superficial bladder carcinoma in situ with Connaught BCG 
(ImmuCyst) significantly increased complete response rate and extended the disease-free 
interval when compared with Doxorubicin (DOX) chemotherapy. In a Canadian study 
where 54 patients were enrolled and were treated with ImmuCyst, 74% showed complete 
response compared with 42% of 60 patients treated with DOX. The median disease-free 
time was 48.2 months for BCG and 5.9 months for DOX treatment. The types and 
severity of adverse reactions were similar for both treatments and were reportedly within 






1.3 Mechanisms of BCG action 
While the mechanisms of its anti-tumour properties are not thoroughly 
understood, it is widely thought to be an acute non-specific immunological response 
intended to rid the bladder of the pathogen and in the process destroys the cancer cells as 




It has been shown that BCG adherence to the bladder wall via fibronectin is 
paramount in initiating subsequent downstream immune responses [19]. Fibronectin is an 
important component of the extracellular matrix. It can bind to the cell surface and 
recognize various biological molecules such as fibrin, collagen, DNA, heparin, and other 
connective components [20]. Pre-treatment of damaged urothelial surfaces with anti-
fibronectin antibodies reduced BCG attachment to the bladder wall and in turn abrogated 
anti-tumour activities in rodent [21].    
 
1.3.2 Recruitment of immune cells 
It is widely accepted that the BCG associated anti-tumour effect is T-lymphocyte 
dependent [22, 23]. After repeated BCG instillations, the bladder wall is infiltrated with 
cluster of differentiation (CD) 4+ and CD8+ T-cells, as well as natural killer (NK) cells 
and monocytes/ macrophages. Bladder washes have been found to be composed largely 
of T lymphocyte populations, with CD4+ T cell dominance.  
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Following BCG internalisation by urothelial tumour cells, BCG is processed and 
presented by the urothelial cells to cluster of differentiation (CD) 4+ T cells via major 
histocompatibility complex (MHC) class II molecules [24]. In vitro quantitative 
immunohistochemistry along with bladder biopsies before and after BCG therapy 
demonstrated an upregulation of MHC class II on urothelial tumour cells [25]. 
Simultaneously, antigen-presenting cells like dendritic cells and macrophages present 
BCG epitopes to T-helper cells culminating in T-cell activation [25] and cytokine 
production.  
Polymorphonuclear (PMN) cells are early innate immune cells and the 
predominant subpopulation of leukocytes in the urine after BCG instillation [26]. They 
migrate to the tumour site site after BCG instillation and mediate the recruitment of 
monocytes and CD4+ T-cells [26]. CD4+ T-cells are a good source of interferon gamma 
(IFNγ) [27] and are potent in activating cytotoxic effector cells such as NK cells [23, 28].   
Cytotoxic effector cells such as NK cells, BCG-activated killer cells, macrophage-
activated killer cells (MAKs), lymphokine-activated killer cells (LAKs) and cytotoxic T 
cells have also been shown to mediate non-specific cell-mediated anti-tumour effects 
[29]. Several papers have verified the role of NK cells in tumour eradication. Brandau et 
al showed that BCG’s anti-tumour effects were completely absent in NK-deficient beige 
mice and in mice pre-treated with anti-NK1.1 monoclonal antibodies, strongly indicating 






1.3.3 Pro-inflammatory cytokines 
Urinary cytokines can be detected in the bladder from as early as the 4th BCG 
instillation and remain detectable for 2 - 8 hours after instillation [31, 32]. Early-response 
cytokines such as interleukin (IL) 1, IL6, IL8 and IL18 [32, 33] have been detected in 
patients’ urine following BCG instillation. After antigen presentation and recognition, 
activated CD4+ T-cells release IL2 and interferon gamma (IFNγ).  
The release of helper T cell response type 1 (Th1) cytokines leads to a cell-
mediated tumour cell eradication. It has been reported that successful BCG 
immunotherapy requires the proper activation of a Th1-skewed immune response 
including the release of Th1 cytokines (IFNγ, IL12 and IL2).  While the presence of Th2 
cytokines (IL10 and/or IL6) in urine usually corresponds to BCG therapy failure [34]. It 
has also been shown with murine orthotopic models that IFNγ and IL12, but not IL10 and 
IL4 are needed for effective therapy [35].  The cytokine cascade in turn leads to the 
infiltration of more monocytes/ macrophages, CD4+ and CD8+ T-cells and NK cells, 
which in turn form chronic granuloma-like cellular infiltrates in the sub-urothelial stroma 
[36, 37]. The process culminates in the eventual clearance of both BCG and tumour cells. 
In addition, Poppas et al [38] demonstrated that interferon-inducible protein 10 
(IP-10) along with IFNγ and IL12, are increased during intravesical BCG immunotherapy 
of superficial bladder cancer. These data suggest that, in addition to a cellular immune 
response, BCG may induce a cytokine-mediated anti-angiogenic environment that aids in 





1.3.4 BCG viability influences treatment efficacy 
The viability of BCG has also been shown to be crucial for induction of a local 
immune response and for effective therapy, i.e. response to therapy is directly related to 
BCG viability. Based on retrospective studies [39, 40] most clinicians and researchers 
believe that BCG viability is crucial for therapeutic efficacy. In one study, most patients 
who failed initial therapy with a low viability lot of BCG responded favourably to re-






















Figure 1.1 Proposed BCG mechanisms. Polymorphonuclear neutrophil (PMN) are the 
first immune cells to arrive in the bladder after BCG (   ) instillation. PMN may be 
directly tumouricidal (   ) or aid in the recruitment of T-helper cells including CD4+ and 
CD8+ T-cells to the bladder. At the same time, some of the instilled BCG accumulates in 
the bladder wall, while others are internalised by the urothelial cells via fibronectin while 
others are internalised by bladder tumour cells. The result is the processing and 
presentation of BCG-derived epitopes (   ) on MHC II, and the eventual activation of 
CD4+ T-cells. Once activated, CD4+ T-cells releases a milieu of Th1 cytokines - IL2 and 
IFNγ, which in turn activate cytotoxic T-cells (Tc), macrophages (Mφ) and natural killer 
(NK) cells leading to BCG clearance and the indirect killing of tumour cells. The release 
of Th1 cytokines recruits more immune cells, heightening the inflammatory response 
contributing to the eventual clearance of both BCG and tumour cells. Green dashed 








1.4 Side-effects associated with BCG immunotherapy  
Despite its proven efficacy, there is a non-responder rate of 30 – 50% [41]. BCG 
therapy is also associated with a range of side-effects, namely fever, haematuria, urinary 
frequency and dysuria, with symptoms of bladder irritability in 90% of the patients [42]. 
BCG is a live bacterium, while its virulence has been attenuated, BCG septicemia 
culminating in death can still occur. Additionally, patients who fail BCG therapy and 
undergo subsequent radical cystectomy seem to have an increased risk for systemic 
progression and death as compared to those who had primary radical surgery [43]. As 
such, there is a pressing need for alternative approaches in treating superficial bladder 
cancer. 
 
1.4.1 Attempts to alleviate BCG side effects 
In order to reduce the side effects of BCG and to improve efficacy, several 
alternatives have been developed namely, 1) generation of genetically engineered BCG 
secreting relevant cytokines e.g. human IFNα-2b to enhance BCG immunogenicity [44], 
or 2) fine-tuning treatment schedules such as varying the type of BCG used. de Boer et al 
studied the use of 3 viable BCG and 3 subsequent instillations with heat-killed BCG in 
mouse models [40, 45] and found that this regimen was comparable to standard 6-week 
viable BCG treatment in its ability to induce cytokine mRNA expressions. In the same 
study, experiments were also carried out with lower doses of BCG, containing at least 3 x 
106 cfu, with the aim of lowering the side effects. But lowering the dose decreased the 
Th1 response. In humans, Ojea et al [46] lowered the BCG dose (81mg) in intermediate-
risk patients to a third (27mg) and one-6th (13.5mg) of the standard BCG dose, and 
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compared it with MMC. It was found that the 27mg group was only slightly better than 
MMC in prolonging the disease-free period, and patients still experienced toxicity despite 
the lowered BCG dose. It has also even been suggested by Lamm et al [47] that the 
efficacy of BCG can be augmented with high dose vitamins (vitamins A, B6, C, and E). 
However, these parameters are still largely experimental and efficacy has yet to be 
confirmed. More recently, some have explored the use of alternative bacteria, e.g. 
lactobacillus species, as adjuvants to transitional cell carcinoma treatment.  
 
 
1.5 Probiotics and Lactobacillus species 
 
Probiotics are defined as “living organisms, which upon ingestion in certain 
numbers exert health effects beyond inherent nutrition” [48]. They are "generally 
recognised as safe" and are currently the subject of intense and widespread research as 
functional foods since they are known to have health benefits, such as possessing anti-
hypertensive activities [49], alleviating antibiotic-induced diarrhoea [50, 51], 
gastroenteritis [52], and food allergies [53].  
Bacteria used in commercial probiotic preparations are most commonly lactic 
acid-producing species including members from the Bifidobacteria, Lactobacillus and 
some Streptococcus genus; e.g. B. longum, L. casei strain Shirota (LcS), L. rhamnosus 
strain GG (LGG), S. thermophilus subsp Salivarius. Other organisms include Escherichia 
coli (e.g. E. coli Nissle 1917), Entercoccus species, Bacteriodes species and various 
yeasts.  
Members in the genus Lactobacillus are gram-positive non-sporulating rod-
shaped bacteria [54]. They are ubiquitous, forming a substantial bulk of the human gut 
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and oral commensals. They are widely consumed as probiotics as part of the human diet 
and strains such as LcS and LGG have a long history of being included in the human diet 
[55]. They have been studied extensively in humans and experimental animals for a wide 
variety of applications. Apart from use in the food and beverage industry, Lactobacillus 
strains have also been genetically engineered for use as oral immunotherapeutics, such as 
vaccination and delivery of immunoregulatory substances. There has also been increasing 
evidence suggesting that Lactobacillus species possess anti-cancer, anti-metastatic as 
well as chemopreventive activities.   
 
1.5.1 Beneficial health properties of Lactobacillus species 
1.5.1.1 Women’s reproductive and bladder health  
Lactobacillus strains are able to colonise the vagina following vaginal suppository 
insertion and reduce the risk of urinary tract infection, yeast vaginitis and bacterial 
vaginosis. The rate of urinary tract infection in 25 women was compared before and after 
regular lactobacillus usage. Prevention of urinary tract infection entailed once-weekly 
vaginal administration of suppositories containing 109 lactic acid bacteria (LAB) for a 
year. The results showed that there was a significant reduction in infection during the 
period of experiment [56]. 
 
1.5.1.2 Alleviating allergies 
Oral consumption of LGG has also been shown to elevate serum IL10 levels 
shifting the immune response towards a Th2 response as such, LGG may be useful for the 
treatment and prevention of atopic disease and other allergic reactions [57].  In a double-
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blind, randomised, placebo-controlled trial involving 132 volunteers over a 2-year period, 
it was found that expectant mothers with previous history of atopic rhinitis, eczema or 
asthma, when administered 2 capsules containing 1010 LGG, had children with a 
significant reduction in the incidence of allergic atopic dermatitis [58].  
 
1.5.1.3 Boosts overall immunity 
There is unequivocal evidence that Lactobacillus species are able to stimulate as 
well as regulate several aspects of the innate and acquired immunity. Tests done with 
mice showed that mice were fed daily with L. rhamnosus, L. acidophilus or B. lactis 
resulted in enhanced phagocytic activity of peripheral blood leucocytes and peritoneal 
macrophages compared with the control mice. The splenocytes from the treatment groups 
also had augmented IFNγ in response to stimulation with concanavalin A than cells from 
the control mice [59]. Immunomodulation of the host’s immune system following the 
ingestion of lactic acid bacteria and related fermented milk products have also been 
shown in human subjects [60, 61].  
At the same time, Lactobacillus species can influence cytokine production at 
mucosal surfaces. Pro-inflammatory cytokines such as IFNγ TNFα, IL12, IL1β, IL18 [62, 
63] and anti-inflammatory cytokines, IL10 and transforming growth factor (TGF) β, have 
been detected in the serum of human subjects following lactobacilli ingestion. The 
released Th1 cytokines enhance the phagocyte-mediated clearance of microorganisms 
and stimulate the proliferation of T, B and NK cells, thereby ensuring and/ or augmenting 




1.5.1.4 Ensuring good gastrointestinal health and prevention of gastrointestinal 
infections  
Lactobacillus species, in particular LGG has been used successfully in the 
treatment of acute and rotavirus diarrhoea in infants and children [64, 65]. It has been 
proposed that lactobacilli ingestion increased the gut immunoglobulin (Ig) A immune 
response hence augmenting the gut immunological barrier [66]. At the same time, 
lactobacilli actively compete with gastroenteric pathogens such as Clostridium difficile 
(associated with antibiotic-induced diarrhoea), Campylobacter jejuni, Helicobacter pylori 
and rotavirus for binding sites on epithelial cells, displacing them thereby preventing 
disease initiation [67 - 70]. Shirori et al found that the ingestion of fermented milk 
beverages containing LcS and transgalactosylated oligosaccharides once a day for 2 
weeks significantly reduced the lecithinase-positive Clostridium and Enterobacteriaceae 
bacteria counts in their human subjects [71].  
The genus Lactobacillus is also known to produce anti-microbial substances 
against gastrointestinal pathogens and other microbes, both Gram positive and negative. 
These inhibitory substances include organic acids [72], hydrogen peroxide [73] and 
bacteriocins [74]. Also, by keeping the gut at a relatively acidic pH via the production of 
lactic acid as a major metabolic by-product, lactobacilli make it difficult for pathogens to 
colonise. It has also been postulated that lactobacilli impede pathogen growth by 
competitive exclusion where lactobacilli deplete the nutrients in the gut.  
At the same time, the gut epithelium is lined by mucin, a gel-like mucus layer of 
glycoproteins, which serves to impede the adhesion of enteropathogens. In vitro studies 
have shown LGG and L. plantarum 299v enhanced the expression of mucin genes 
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(MUC2 and MUC3) in colonic epithelial cells (HT-29) [75], suggesting that 
Lactobacillus species may exert their anti-infective effects by augmenting mucin gene 
composition, expression as well as the release of mucous.  
 
1.6 The genus Lactobacillus and cancer 
It has been shown in epidemiological and animal studies that regular consumption 
of fermented dairy products such as yoghurt and fermented milk containing Lactobacillus 
species may be related to a lower incidence of number of cancers. Seperate studies in 
France, the Netherlands and the United States have found that frequent consumption of 
yoghurt or fermented milks have protective effects over breast and colon cancers [76, 77, 
78]. Animal studies have also shown the administration of L. bulgaricus strain LBB.B 
144 (product FFM.B 144) can inhibit intestinal carcinogenesis induced by 1,2-
dimethylhydrazine in rats [79].  
There are numerous other publications documenting and detailing the anti-cancer 
and chemopreventive activities and mechanisms of various commercially available 
Lactobacillus species. There are at least three groups within the genus Lactobacillus that 
are found to be effective against cancer onset and disease progression. They are: 1) L. 
acidophilus group, 2) L. casei group, 3) L. reuteri/ fermentum group. While their use as 
cancer immunotherapueitcs is equally promising, the groups differ in abilities to ferment 
sugars and have different cell wall/ surface characteristics. It is thus possible that 
different strains mediate different cancer killing mechanisms. The following section 




1.6.1 Postulated anti-cancer mechanisms of Lactobacillus species 
1.6.1.1 Alteration to gut microflora 
A diet rich in fats and red meat encourages the growth of putrefactive bacteria. 
The latter has been shown to break down food and produce carcinogens. The ingestion of 
Lactobacillus species lowers the pH of the gastrointestinal tract because lactic acid is a 
major metabolic by-product of the genus Lactobacillus [80]. As a result of the acidic gut 
environment and competitive exclusion by lactobacilli, the growth of the putrefactive 
bacteria is impeded, thereby leading to a reduction in carcinogen generation [80].   
 
1.6.1.2 Alteration to metabolic activities of gut microflora 
Oral administration of LGG has been shown to suppress β-glucoronidase, 
glucoronidase, nitroreductase and azoreductase [61, 71], all of which are bacterial 
enzymes capable of activating procarcinogens in the large intestines [81, 82]. The 
carcinogenic potential of these putrefactive bacterial enzymes have been described in a 
number of studies [83]. In a recent study conducted by De Preter et al, which involved 
healthy volunteers consuming LcS and B. breve. After the 4-week experiment, there was 
decreased β-glucuronidase activity in the volunteers [84]. 
 
1.6.1.3 Adsorbing and facilitating excretion of carcinogens 
It was also found that the cell wall of Lactobacillus species can effectively bind to 
potential carcinogens such as heterocyclic aromatic amines formed during cooking of 
meat [85], thereby facilitating their degradation and expulsion from the blood plasma, 
urine and gastrointestinal system, hence reducing cancer risk. Lidbeck et al demonstrated 
  
18
that L. acidophilus administration to healthy volunteers increased the number of faecal 
lactobacilli, which corresponded to lower mutagen excretion, particularly in urine [86]. 
Hayatsu and his colleague also demonstrated a significant reduction (6 - 67%, average 
47.5%) in urinary mutagenicity following LcS ingestion by 6 healthy non-smoking 
volunteers [87].   
In summary, there are three postulated mechanisms via which the genus 
Lactobacillus may mediate its anti-tumour activities: 1) inhibiting the growth of 
putrefactive faecal coliforms responsible for converting precarcinogens to carcinogens; 2) 
inhibiting tumour formation; and 3) binding and/ or inactivating carcinogens (Figure 1.2). 
While some have suggested that bacterial viability is a prerequisite to anti-cancer 
activities, others have shown that heat-killed cells and even soluble bacterial components 


















Figure 1.2.Mechanisms via which Lactobacillus species impede cancer formation. 
Lactobacillus may mediate its anti-tumour activities by inhibiting carcinogen production 



























1.6.2 Lactobacillus species and Bladder Cancer 
Aso et al also demonstrated in 2 separate human studies, the preventive effects of 
LcS preparations on the recurrence of superficial bladder cancer in patients. In both 
studies, no adverse side-effects were observed suggesting that the oral administration of 
LAB including lactobacillus preparations to patients is useful and safe [91, 92].  
Using the murine subcutaneous bladder cancer model to allow day-to-day 
monitoring of tumour progression, Lim et al reported that C57BL/6 mice that were 
implanted with subcutaneous bladder tumour and fed immediately with LGG hardly 
developed tumours and where tumour developed, the tumour burden was small. They 
found an increased spleen T-helper, cytotoxic T-lymphocyte and NK cells in mice fed 
with LGG compared to control phosphate buffered saline (PBS) -fed tumour-bearing 
mice. There was an increase in lymphocytes and granulocytes in tumour sections, 
especially in the immediately fed group as compared to the controls. These evidence 
suggest that oral consumption of LGG may prevent tumour growth via modulation of the 
immune system [93]. 
Takahashi et al [94] reported in a mouse bladder tumour (MBT)-2 orthotopic 
bladder tumour model with C3H/He mice that the intravesical instillations of LC9018 (a 
heat-killed preparation of LcS) augmented the local expression of IFNγ and TNFα 
mRNA and induced the infiltration of neutrophils and macrophages in the bladder 
mucosa. Using immunohistochemical techniques, they detected phagocytosed LC9018 
cells in the bladder mucosa macrophages.  
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In vitro experiments have also demonstrated that both LcS and LGG can inhibit a 
number of human bladder cancer cells’ proliferation (MGH and RT112) and induce a 
large number of phosphotidylserine-positive pro-apoptotic cells [95].  
 
1.7 Unanswered questions and inconsistencies in current reports 
Despite the wealth of information on the cancer prophylactic potential of 
Lactobacillus species, there is however limited information on the pathways via which a 
particular Lactobacillus species may elicit its anti-tumour mechanisms and it may even 
be plausible that different bacterial strains use different mechanisms.  
Also, although Takahashi’s group [94] was the first to successfully report the 
intravesical use of LcS as an adjuvant to superficial bladder cancer therapy, however they 
used an instillation schedule of once daily for 10 days as opposed to the clinical practice 
of 1 instillation per week for 6 consecutive weeks. LGG data from Lim et al [93] may not 
have been representative since they used the subcutaneous bladder cancer model, which 
was not a definitive representation of the host’s hormonal or immunological processes.  
In addition, since most of the case-controlled clinical and animal data are derived 
from LcS and there have been criticisms that studies should also be conducted with 
probiotic strains other than LcS since, LcS is not generally available for patients with 
bladder cancer outside of Japan [96]. It would thus be interesting to determine if other 






1.8 Lactobacillus rhamnosus strain GG (LGG) 
LGG is a member of the L. casei group [97], and it is one of the few lactobacilli 
that can ferment rhamnose. While LcS is widely consumed in the Eastern hemisphere, 
LGG-related fermented milk products are popular in the West.  
In vitro data has demonstrated LGG’s potential as an adjuvant in bladder cancer 
therapy [95], but current data requires correlation with in vivo assays in order to render 
biological significance. As such animal experiments along with additional in vitro tests 
will be designed to contribute more information on LGG’s immunotherapeutic potential.  
 
1.9 Animal models of bladder cancer 
Several animal models of bladder cancer have been developed to aid in the 
investigations of the disease. The advantages of using animal models is that data from 
these in vivo systems can give further insight into disease progression and evaluation of 
drug mechanisms. Currently, there are three animal bladder cancer models: 1) chemically 
induced bladder cancer, 2) xenograft model, and 3) syngeneic tumour models. 
The chemical induction of tumours best represents the development of human 
bladder cancer. It involves the incorporation of genotoxic compounds, such as N-[4-(5-
nitro-2-furyl)-2-thiazolyl] formamide (FANFT) into the diets of experimental animals for 
prolonged periods (8 – 11 months) [98]. Tumours induced by this compound are 
predominantly transitional cell carcinoma [99].  Transplantable cell lines have been 
developed from these FANFT-induced tumors, the most commonly used are labeled 
MBT-2 and AY-27 derived from C3H/He mice [100] and Fisher rats respectively [101]. 
However, being complete carcinogens, the use of this compound presents safety concerns 
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for the researchers involved and it is also time-consuming since the tumours take a long 
time to develop. 
The xenograft model involves the heterotransplantation of various human bladder 
cancer cells into immunodeficient mice [102]. The main advantage of this model is that 
they allow the study of aspects of tumour biology, such as patterns of growth and 
differentiation, the expression of tumor antigens, and response to treatment [103, 104]. 
However the immunodeficient mice are compromised in their ability to develop an 
adequate immune reaction to an immunological stimulus and as such do not accurately 
represent physiological conditions.  
The syngeneic model involves the implantation of bladder cancer cells into naïve 
immunocompetent animals of the same strain [105]. Bladder tumours may be 
subcutaneously implanted (heterotopic model) but the subcutaneous tumour model is 
limited in its contribution to bladder cancer knowledge since it is questionable if the 
tumour development at these non-native sites are equivalent to the development of the 
tumour in the organ of its origin [106].  
On the other hand, the orthotopic syngeneic bladder tumor model implants 
tumours at the anatomical site and has been successfully used for evaluation of efficacy 
of keyhole limpet hemocyanin, chemotherapeutics and intravesical BCG. Consequently, 
the tumour can be directly exposed to intravesical anti-cancer drugs in its natural 
environment.  
Currently, there are two orthotopic bladder cancer models: 1) MB49 cells in 
C57BL/6 mice and 2) the mouse bladder tumour-2 (MBT-2) cell line in C3H/He mice. 
The MBT-2-C3H/He murine orthotopic model is reportedly not responsive to BCG 
  
24
therapies [107] and as such, it is not conducive for comparing LGG and BCG treatment 
efficacies. Apart from this, a major drawback of these models is the inability to monitor 
tumor growth accurately. To circumvent this, Wu et al produced a bladder tumour cell 
line (MB49) that secreted human prostate-specific antigen (PSA) [108], with the aim of 
using PSA as a biomarker for monitoring orthotopic bladder tumour growth. The 
implication then was, only mice with successful tumour implantation will test positive for 
urine PSA; tumor burden was evaluated by enzyme-linked immunosorbent assay 
(ELISA) measurement for PSA in urine and bladder tissues. 
Traumatisation of the bladder surface must precede tumour implantation and may 
be achieved by electrocautery with a cautery wire [109]. Traumatisation is also achieved 
by instillations of N-methyl-N-nitrosourea [110, 111] or silver nitrate [112]. Tumour 
implantation efficiency with these traumatisation techniques are largely operator-
dependent and unpredictable, due to  insufficient acid neutralization (if acid was used) or 
poor current conductivity due to confounding factors such as urine and the 
glycoaminoglycan (GAG) layer.  
The use of poly-L-lysine (PLL) before tumour cell implantation in the orthotopic 
bladder tumour model was first described by Loskog et al [113]. PLL is a polycation and 
when instilled into the mouse bladder enabled the negatively-charged tumour cells to be 
‘glued’ the positively-charged PLL-coated bladder wall, and so obliterates the need for 
technically advanced equipment such as those used in the electrocautery tumour 
implantation methods. PLL was also superior to other orthotopic tumour implantation 
techniques as it consistently yielded 100% tumour implantation efficiency without having 
to induce prior bladder traumatisation.  
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Tables 1.2 and 1.3 summarise the conventional methods used to induce and 













































Table 1.2 Methods for studying bladder cancer 
Model Mode of 
Induction/ 
implantation 
Advantages Disadvantages Reference 
Subcutaneous Subcutaneous • Ease of monitoring 
disease progression 












• Syngeneic model 
• Tumour in native 
organ 
 
• 8 - 11 months before 
mice developing 
bladder cancer  








• Single tumour 
• Syngeneic model 
• Immunocompetent 
host 













• High implantation 
efficiency 
• Reproducible 
• Tumour directly 
attached to the 
bladder surface 
• Low risk of 
puncturing bladder 
wall 
• Syngeneic model 
• Tumour in native 
organ 





• Syngeneic tumour 
model  








• Syngeneic tumour 
model 
• Low implantation 
efficiency 
[110, 111]  
Xenograft Transplantatio




• Allow direct human-
xenograft 
comparisons of 
response to treatment  
• Immunodeficient 
mice 
• Nude mice  





Table 1.3 Animal models for studying bladder cancer 
Animal 
Strain 
Cell Line Advantages Disadvantages Reference 
C3H/He MBT-2  
 
Syngeneic  • Does not respond 






sacrificing animals  
[116, 100] 






















• PSA (foreign to 
host) may result in 
immune response 
[108] 






Taken together, the PLL-induced, MB49-PSA tumour cell line orthotopic model 
is the model that is likely to give the highest tumour implantation efficiency and at the 
same time allow the monitoring of disease progression. As such it will be used for the 
purpose of evaluating and elucidating lactobacillus’ anti-tumour mechanisms in bladder 
cancer. Since it is also the aim of this dissertation to study host immune response toward 





1.10 Types of cell death in cancer treatment 
Metabolic and therapeutic stresses can simultaneously provoke a series of 
adaptive responses and suicide signals in cancer cells. The sum of these programmed 
adaptation and death signals determines death or cell survival. Understanding the 
processes that contribute to cancer cell death and survival can significantly influence 
therapeutic efficacy or mortality, for example, the extensive characterisation of apoptosis 
pathways has allowed the development of targeted therapies designed to induce apoptotic 
cell death. 
In vitro studies of cancer cells have allowed investigators to categorise responses 
to cellular stress by morphologic and biochemical criteria into at least 3 forms of cell 
death: apoptosis, autophagy, and necrosis [119].  
Earlier work had provided some evidence of LGG and LcS initiating apoptosis 
bladder cancer cells [95], but little else is known.  Therapeutic stresses can provoke a 
series of suicide signals in cancer cells. Apoptosis, autophagy and necrosis are 3 forms of 
well-characterised cell deaths, all of which elicit different responses from the host 
immune system, which may sometimes facilitate tumour cell immune evasion. By 
capitalising the type of cell death induced, therapeutic strategies can be maximised to 
ensure irreversible tumour cell death leading to successful tumour eradication.  
 
1.10.1 Apoptosis 
Apoptotic cells are rapidly degraded and cleared by phagocytes. Upon undergoing 
apoptosis, the endoplasmic reticulum associated protein, phosphotidylserine (PtdSer) 
translocates to the cell surface membrane [120]. The expression of PtdSer on the plasma 
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membrane suppresses the release of proinflammatory cytokines by phagocytes [121], and 
therefore, apoptosis is largely an immune-silent form of cell death.  
 
1.10.1.1 Nonsteroidal anti-inflammatory drugs activated gene 1 
Nonsteroidal anti-inflammatory drugs (NSAID) activated gene 1 (NAG-1) is a 
member of the tumoue growth factor (TGF) β family. It has been reported to possess anti-
tumourigenic and pro-apoptotic activities in vitro and in vivo [122, 123]. Many 
investigators have reported that anti-tumourgenic compounds such as linoleic acids [124] 
and epicatechin gallate [125] can induce NAG-1 expression. NAG-1 upregulation has 
been associated with a simultaneous increase in pro-caspase 3 and poly (ADP-ribose) 
polymerase (PARP) cleavage leading to cell death [126]. Shin and others have described 
how forced NAG-1 expression could significantly induce apoptosis and death receptors-4 
(DR-) and DR-5 expression culminating in apoptosis [127]. Other in vitro data have 
demonstrated NAG-1 upregulation and expression enhancing apoptotic effects induced 
by herbal diptheroids [128] or queretin [129] in colorectal cancer cells, but little is known 
of its effects in bladder cancer cell. To date, there is very little information on 
Lactobacillus species’ ability to induce apoptosis, and if it is initiated via NAG-1. 
 
1.10.2 Necrosis 
Necrotic cell death is often regarded as unscheduled and ‘messy’ cell death. The 
disruption of the plasma membrane leads to the spillage of intracellular metabolites that 
activates the host immune response in a deleterious manner [130, 131]. Although 
apoptosis is largely immune silent or immunosuppressive, therapy-induced necrotic cell 
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death initiates an immune response to tumour cells. Whether the inflammation associated 
with necrosis is desirable or leads to further tumour growth is still under debate. 
 
1.10.3 Autophagy 
Autophagy is a multistep process that involves the vesicular sequestration of long-
lived cytoplasmic proteins and organelles such as mitochondria [119]. The resulting 
double-membrane vesicle is termed an autophagosome. Autophagosomes fuse with 
lysosomes, and through the action of acid-dependent enzymes, degradation of 
autophagosome contents ensues. Autophagy has been observed in cancer cells faced with 
a variety of metabolic and therapeutic stresses. Autophagy is a reversible process that can 
contribute both to tumor cell death and survival. Once activated, persistent autophagy and 
the eventual depletion of cell organelles and critical proteins, can lead to a caspase-
independent cell death [119]. 
Cells undergoing any one of the 3 forms of cell death present with different 
morphologies and culminate in different immune reactions with different implications for 
cancer therapy. The defining characteristics of the 3 types of cell death are summarised in 















Table 1.4. Characteristics of apoptosis, necrosis and autophagy.  
Type of 
cell death  
Morphology Immune reactions 
Apoptosis Chromatin condensation, nuclear and 
cytoplamic blebbing, apoptotic bodies 
 
Suppression of inflammation 









Lactobacillus species along with their fractions have been shown to induce 
apoptosis in colon cancer cells [132, 133] as mechanisms against colon cancer, but it is 
not known if LGG can do the same in bladder cancer cells and if so, what the likely 






















1.11 Scope of study 
To date, there is limited literature documenting the intravesical use of Lactobacillus 
rhamnosus GG as an adjuvant to superficial bladder cancer therapy in vivo. Based on 
evidence derived from Takahashi’s [94] and Lim’s [93] orthotopic and subcutaneous 
bladder cancer model respectively, this dissertation aims to further characterise the anti-
tumour mechanisms of LGG in the following manner:  
 
1. Using the murine orthotopic tumour (MB49-PSA) model, we will compare LGG and 
BCG, the current gold standard, as an adjuvant intravesical agent in treating 
superficial bladder cancer.  
 
2. Optimise an effective schedule at which LGG is efficacious as an adjuvant 
intravesical immunotherapeutic agent.  
 
3. Determine the systemic and surrounding immune responses following LGG 
intravesical instillations hence understanding the likely immunomodulatory events 
triggered by LGG. 
 





























2.1 Bacteria culture 
2.1.1 Lactobacillus rhamnosus strain GG (LGG) 
Standard growth curves were produced by plotting OD550nm versus number of 
bacterial colonies of freshly prepared, serially diluted cultures on de Man, Rogosa, 
Sharpe (MRS) (Merck, Germany) agar plates. It was determined that an overnight culture 
of LGG (National Collection of Industrial and Marine Bacteria, Ltd., Aberdeen, 
Scotland) consistently yielded 3 x 109 colony forming units/ml (cfu/ml). 
Overnight cultures of LGG were routinely used for the experiments. The bacteria 
were grown and maintained in MRS media (Merck) at 37oC. For experiments using 
mammalian cell culture media the bacteria were harvested by centrifugation at 4,000 rpm, 
for 10min (Eppendorf Centrifuge, Germany) and rinsed once with 1x PBS (4.3 mM 
Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.4 mM KH2PO4; pH 7.4). To avoid strain 
variation from prolonged culture, new LGG glycerol stocks were thawed to start a fresh 
culture every 2 - 3 months. 
 
2.1.2 Heat-killed LGG 
Heat-killed LGG was prepared by incubating bacterial cultures in an 80oC water 
bath for 1hr.  Complete loss of cell viability was verified by monitoring colony formation 
on MRS agar plates. 
 
2.1.3 Lyophilised LGG (Lyo LGG) 
LGG was lyophilised according to Benkerroum et al [134] with some 
modifications. Briefly, pellets produced from overnight cultures of LGG were washed 
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with saline then centrifuged (4,000 rpm, 10 min). The bacterial pellet was frozen at -80oC 
before being lyophilised overnight in a freeze-dryer at -40oC with a vacuum pressure of 
400mbar (Thermo Savant, USA). To determine the viability after lyophilisation the 
bacterial pellet was re-suspended in 1 ml saline (0.9% w/v NaCl [Sigma Aldrich, USA]) 
using a 24G needle, washed with 10 ml saline and pelleted by centrifugation. The pellet 
was resuspended and viability was determined with standard bacterial plating techniques.  
 
2.1.4 LGG-green fluorescent protein (LGG-GFP)  
LGG-GFP was a gift from Prof Chua Kaw Yan, Pediatrics Department, National 
University of Singapore, Singapore. LGG-GFP was cultured in MRS media 
supplemented with 10µg/ml erythromycin (Sigma) and used to differentiate instilled 
bacteria from the natural flora.  
 
2.1.5 Live Bacillus Calmette Guerin (BCG) 
BCG (substrain Connaught) was grown in 7H9 Middlebrook medium (Difco, BD 
Biosciences, USA) supplemented with 10% ADC supplement (0.85% NaCl, 5% bovine 
serum albumin fraction V, 2% dextrose and 0.003% catalase), 0.05% Tween 80 and 0.2% 
glycerol. BCG was harvested at an absorbance of 0.7-0.8 (the exponential phase) at 
OD600nm (Shimadzu, Japan) and resuspended in 1xPBS prior to instillation in the mice. 
OD600nm   0.1 = 2.6 x 106 cfu/ml. All chemicals were sourced from Sigma unless 





2.2 Tumour cell lines 
MGH (human bladder cancer cells) and a murine transitional cell carcinoma cell 
line (MB49) were maintained in RPMI 1640 media (Sigma) supplemented with 2mM L-
glutamine (Sigma Aldrich), 10% v/v foetal bovine serum (FBS) (Hyclone, USA) and 
5000U/ml Penicillin and 5mg/ml Streptomycin (Sigma) hereafter referred to as PS media. 
MB49 cells were obtained from Dr. Timothy Ratliff at the University of Iowa 
MB49-PSA cells, which were MB49 stably transfected with the human prostate 
specific antigen (PSA) prepared as described previously [108] were maintained as per 
MB49 cells, but with the addition of hygromycin (Invitrogen Life Technologies, Inc., 
USA) at a concentration of 0.2mg/ml.  
 
2.3 Animals 
4 – 6 week old female C57BL/6 mice (Centre for Animal Resources [CARE], 
Singapore) were maintained at the National University of Singapore’s (NUS) Animal 
Holding Unit (AHU) throughout the duration of the experiment with food and water ad 
libitum. The mice were acclimatised for a week prior to the start of each experiment. All 
experiments were performed according to guidelines set by the NUS Institutional Animal 
Care and Use Committee (IACUC).  
 
2.3.1 Orthotopic procedures 
The mice were anesthetised by an intra-peritoneal injection of ketamine and 
medetomidine (0.1ml/10g body weight) obtained from the AHU, prior to all orthotopic 
procedures. Intravesical instillations were carried out using 24G catheters (B.Braun, 
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Germany); to minimise voiding activities, the catheters were kept in place with a Luer-
Lock closing cone for 2 hr. To avoid cross-contamination the catheters were not reused 
between mice. After the procedures, the mice were revived with equal volumes of the 
anaesthesia antidote, Antisedan (0.1ml/10g body weight) (AHU) and returned to their 
respective cages after treatment.  
 
2.3.2 Assessing the safe use of LGG in mice 
Mice bladders, lymph nodes and other tissues were harvested from mice after live 
LGG instillation(s) to determine live LGG persistence within the host post-instillation 
and its effects on the host immune system. The following sections and Figure 2.1 
summarise the various analysis done.  
 
2.3.2.1 LGG localisation and translocation 
Healthy mice were administered 1 or 6 intravesical instillations of 1 x 108 cfu 
LGG-GFP/100 µl (treatment group) or PBS (control). The mice were sacrificed after 6, 
24 and 48 hr and 1 week post-instillation. The draining lymph nodes, spleens, bladders 
and kidneys were collected, homogenised and the homogenates (up to 106 dilution) plated 
on MRS agar supplemented with erythromycin (1 µg/ml) and the bacteria colonies were 
enumerated.  
 
2.3.2.2 Immune cell population changes after bacteria instillations in healthy mice  
Healthy mice that were administered LGG instillations (1x108 cfu) were 
terminated 6 hr after the 4th or 6th instillation; bladders, spleen and draining lymph nodes 
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were resected for immune cell profiling. The tissues were placed in a 6-well culture plate 
on ice and cut into fine pieces. Subsequently they were digested with collagenase 
resuspended in complete media (1mg/ml per tissue) for 30min at 37oC with shaking. The 
suspension was then filtered through a 7µm cell strainer (BD Falcon, USA) and collected 
in a 2ml tube, then centrifuged at 8,000rpm (4oC, 2min). The supernatant was removed 
and the pellet subjected to red blood cell (RBC) lysis using RBC lysis buffer (150mM 
NH4Cl, 10mM KHCO3, 0.1mM EDTA). The lysed suspension was then centrifuged at 
8,000rpm (4oC, 2min) and the cell pellet was rinsed twice with cold PBS. The cells were 
finally resuspended in 1ml PBS with 0.01% sodium azide, 1% (w/v) bovine serum 
albumin (BSA) and 0.1% formaldehyde for flow cytometry analysis. All chemicals for 
this experiment were supplied by Sigma Aldrich unless otherwise stated.  
The cells were assessed for T cells using anti-CD3 antibody conjugated to 
fluorescein isothiocyanate (FITC), anti-CD4 antibody conjugated to phycoerythrin (PE) 
(T-helper cells) and anti-CD8a-PE (Cytotoxic T-cells). Macrophages and NK cells were 
detected with anti-Mac3-FITC and anti-Pan NK cells-PE respectively. Anti-CD11c-FITC 
and anti-CD83-PE (eBioscience, USA) was used to identify mature, while Anti-CD11c-
FITC anti-CD86-PE were for activated dendritic cells. B-cells were either detected with 
either anti-B220-PE or anti-CD19-FITC. Granulocytes and/ or neutrophils were detected 
with anti-Ly6G-FITC antibodies. Appropriate isotype controls were also included in the 
experiments. Table 2.1 lists the antibodies and the respective isotype controls used for 
this experiment.  
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Immune cells were identified based on forward and side-scatter characteristics 
and their binding with anti CD45-PE and this was used to gate the population of cells for 
further analysis. Only viable cells were analysed. All antibodies were from BD 
Pharmingen (USA) unless otherwise stated and flow cytometry was performed on 
CyAnADP (Dako Cytomation, Sweden). The data obtained was analysed with Summit 
software.  
Table 2.2.List of antibodies used for flow cytometry. 
Immune Cell Type Antibodies Isotype control 
CD4+ T-cells 
FITC rat anti-mouse CD3 
 
Rat (SD) IgG2b, κ 
(FITC) 





FITC rat anti-mouse CD3 
 
Rat (SD) IgG2b, κ 
PE rat anti-mouse CD8a (Ly-
2) 
Rat (Lou/WS1/M) 
IgG2a, κ (PE) 
Granulocytes & Neutrophils FITC rat anti-mouse Ly6G 
 
Rat IgG2a, κ (PE) 
B-cells 
FITC rat anti-mouse CD19 
 
Rat (LEW) IgG2a, κ 
PE rat anti-mouse B220 
 
Rat IgG2a, k 
Macrophages  FITC rat anti-mouse Mac 3 Rat [LewisantiBN]F1 IgG1,κ (FITC) 
Natural killer cells  PE rat anti-mouse Pan NK 
cells Rat IgM,κ (PE) 
Activated dendritic cells  
APC hamster-anti mouse 
CD11c 
Armenian hamster 
IgG1, λ2 (PE) 
PE rat-anti mouse CD83 
 
Rat IgG1 (FITC) 
Mature dendritic cells  
APC-hamster anti mouse 
CD11c 
Armenian hamster 
IgG1, λ2 (PE) 
PE rat-anti mouse CD86 
 
Rat IgG2a, κ (PE) 
‘APC’ signifies antibodies conjugated to allophycocyanin; ‘FITC’ signifies antibodies 





2.3.2.3 Expression of inflammatory cytokines and receptors after LGG instillation in 
healthy mice  
The Oligo GEArray is a pathway-focused DNA microarray. The nylon membrane 
array matrix is coated with 60-mer oligonucleotide probes to detect 112 different 
chemokine, cytokines and their receptors. The following segment describes the protocol 
used to isolate total RNA, label cRNA and the eventual chemiluminescent detection with 
X-ray film for image acquisition. 
Briefly, 1 bladder sample from each treatment group (Control untreated, live BCG 
and live LGG) was harvested 6 hr after the 6th instillation and placed in separate 2ml 
cryovials, cut into fine pieces before they were homogenised (Polytron, Switzerland) in 
1ml Trizol (Invitrogen) while on ice. The homogenates were transferred to clearly 
labelled microfuge tubes before the addition of 0.2ml of chloroform (Sigma). The 
mixture was then shaken vigorously for 15 sec and incubated at room temperature (RT) 
for 3 min. After incubation, the tubes were centrifuged at 12, 000 rpm for 15 min (4oC). 
The aqueous phase was transferred to new 1.5 ml tube before the addition of 0.5ml 
isopropanol (Sigma), and allowed to incubate for 10min (RT). Following that, the 
samples were centrifuged (12, 000 rpm, 10min, 4oC); the supernatant was carefully 
removed and 70% v/v ethanol (Sigma) was added and the tubes were centrifuged (7,500 
rpm, 4oC). After removing the supernatant, the total ribonucleic acid (RNA) content was 
air-dried for 30 min, RT. Following that, the RNA pellet was resuspended in 50µl diethyl 
pyrocarbonate (Sigma)-treated water (DEPC H2O). The RNA sample was heated at 60oC 
(5 min) to facilitate RNA re-solubilisation.  
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The following section describes the isolation of polyA+ mRNA using the 
Oligotex Kit from Qiagen (Germany). Briefly, 250µl RNAse-free water and 15µl 
Oligotex Suspension was added to the entire volume of total RNA isolated earlier. The 
samples were then incubated for 3 min at 70oC to disrupt the secondary structure of the 
RNA. After incubation, the samples were left at room temperature for 10 min to facilitate 
hybridization between the Oligotex particles and the poly A+ tail of the mRNA. The 
Oligotex: mRNA complex was collected by centrifugation for 2 min and the supernatant 
was carefully removed. The complex was resuspended in 400µl of buffer OW2 before 
centrifugation for 1 min in a spin column. The flow through was discarded and 400µl of 
Buffer OW2 was added to the spin column and centrifuged for 1 min. The spin column 
was transferred to a new RNase free microfuge tube and 30µl of hot Buffer OEB (pre-
warmed to 70oC) was added to the column and centrifuged for 1 min. An additional 50µl 
of hot Buffer OEB was added to the column and centrifuged to ensure maximal yield. 
The eluate containing polyA+ mRNA was stored in -80oC until ready for use. 
The following steps describe the labelling of polyA+ mRNA with the 
TrueLabeling-AMPTM Linear RNA Amplification Kit from SuperArray for 1 sample. 
Briefly, 9µl of poly A+ mRNA from each sample was used for the labelling procedure. 
1µl Component G1 was added to 9µl of poly A+ mRNA and the contents were mixed 
gently and collected by centrifugation before incubation at 70oC for 10 min. The mixture 
was centrifuged briefly at the end of incubation and then immediately placed on ice. Prior 
to cDNA synthesis, a 10 µl master mix which consisted of 4µl of RNase-free water, 4µl 
5x cDNA Synthesis Buffer (G3), 1 µl RNase Inhibitor (RI) and 1 µl cDNA Synthesis 
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Enzyme Mix (G2) was prepared and then added to the Annealing Mixture (9µl of poly 
A+ mRNA and 1µl of Component G1). The samples were incubated at 42oC for 50 min.  
In the mean time, the Amplification Master Mix consisting of 16µl 2.5x RNA 
Amplification Buffer (G4), 2µl Biotin-16-UTP (Roche), 2µl Amplification Enzyme Mix 
(G5) was prepared. After placing an array into a hybridization tube, 20µl of the 
Amplification Master Mix was used for the cDNA sample and incubated overnight (at 
least 18 hr) at 37oC to generate cRNA. 
The cRNA generated earlier was purified with the SuperArray ArrayGrade cRNA 
Cleanup Kit. Briefly, 60 µl RNAse-free water was added to each cRNA sample to 
achieve a final volume of 100 µl. Following that, 350 µl of Binding Buffer (G6) to each 
reaction mixture and the contents were mixed gently with a pipette before the addition of 
350 µl of absolute ethanol. After mixing the contents, the samples were loaded into the 
centre of spin columns and centrifuged for 30 sec at 8,000 rpm. The flow through was 
discarded after this step, and the column was placed back into the collection tube and 
washed with 600 µl of Washing Buffer (G7) before centrifuging for 30 sec at 8,000 rpm. 
The flow through was again discarded before the addition of another 200 µl of Washing 
Buffer followed by centrifugation for 3 min at 11, 000 rpm. After this, the spin column 
was transferred to a new Elution Tube and 50 µl of RNase-free water was added to the 
center of each spin column and incubated at room temperature for 2 min. To elute the 
cRNA, the spin column was centrifuged for 1min at 8, 000 rpm.  
The following segment describes the cRNA-array hybridisation process. Prior to 
hybridizing the cRNA to the array, the array was hydrated with 5ml of ddH2O in a 
hybridization tube and left to sit for 5 min. During this time, the GEAhyb Hybridization 
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Solution was warmed to 60oC and 2ml of this solution was added to the membrane 
(array) after discarding the water, and incubated for 24 hr at 60oC. Following this, the 
pre-hybridization solution was discarded and the Target Hybridization Mix (5µg of biotin 
labelled cRNA in 1ml of pre-warmed GEAhyb Hybridization) was added. The 
hybridization was allowed to proceed overnight at 60oC with continuous agitation in a 
hybridisation chamber (Cleaver, USA).  
Following hybridization, the membrane was washed twice (10 min each wash) 
with 5ml of Wash Solution 1 (2x SSC and 1% SDS in ddH2O; chemicals from Sigma) at 
60oC. Then the membrane was washed for exactly 7 min at 60oC with 5ml Wash Solution 
2 (0.1X SSC and 0.5% SDS). After discarding the wash solution the membrane was 
allowed to cool without letting drying before proceeding with chemiluminescent 
detection with the SuperArray Chemiluminescent Detection Kit. 
All the detection steps were performed at room temperature. 2 ml of GEA 
blocking Solution Q was added to the hybridization tube containing the membrane and 
incubated for 40 min with continuous agitation. In the mean time, the AP-SA was diluted 
10,000-fold in 2ml of 1x Buffer F. The diluted AP-SA was added to the membrane and 
incubated for exactly 10 min with continuous but gentle agitation. Following that, the 
membrane was first washed 4 times with 4ml of 1x Buffer F (5 min each wash) with 
gentle agitation and then twice with 3 ml of Buffer G. 1ml of CDP-Star 
chemiluminescent substrate was added to the hybridization tube with the membrane still 
inside and incubated for 2 min. Then using a clean pair of gloves and clean forceps the 
membrane was transferred to a Saran wrap; excess substrate was blotted off with clean 
paper tissues before placement into a film cassette. The membrane was exposed to an X-
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ray film for various time intervals - 2, 5, 10, 15, 30, 45 min and 1 hr. A scanned tagged 
image file format (TIFF) image of the array was then analysed with the GEArray 
Expression Analysis Suite (SuperArray).  
After normalisation with the endogenous controls and background subtraction, all 
genes that were found to be differentially expressed by 2-fold were when compared to 
control were considered significant and subjected to further analysis by reverse 
transcriptase polymerase chain reaction.  
 
2.3.2.4 Reverse transcriptase polymerase chain reaction (RT-PCR) 
To corroborate the oligo array data, bladders from mice that received 4, 5 and 6 
weekly instillations were harvested. 80 units M-MuLV Reverse Transcriptase (New 
England Biolabs, USA) was used to generate complementary deoxyribonucleic acid 
(cDNAs) from 1µg total RNA. Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH), 
chemokine (C-C motif) ligand 2, Ccl5, Ccl6, Ccl7, Ccl8, Ccl17, Ccl19, Ccl21a and 
Ccl22, Chemokine (C-X-C motif) ligand 1, Cxcl2, Cxcl9, Cxcl10, Cxcl14, chemokine (C 
motif) ligand 1 (Xcl1), IL1β, IL16, IL18, IL1r1, IL1r2, Ras-related C3 botulinum toxin 
substrate 1 (Rac1), small inducible cytokine subfamily E, member 1 (Scye1), Fc epsilon 
receptor (Fcεr1g), Fc gamma receptor 1 (Fcγr1), TNFα, and inductible nitric oxide 
synthase (iNOS) were amplified using specific primers sets (listed in Table 2.2).  
For IL2, IL4, IL10, IL12p35, IL12p40, granulocyte-macrophage colony-
stimulating factor (GMCSF), IFNγ, Forkhead box P3 (Foxp3), toll-like receptor (TLR) 2, 
TLR5, TLR9, TGFβ, β-Defensins 1 and 3, 5 µg total RNA and 80 units of Superscript II 
RNase H- Reverse Transcriptase (Invitrogen) were used for cDNA synthesis. All the 
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specific primer sequences used for PCR amplification are listed in Table 2.2 and were 
supplied by 1st BASE Pte Ltd, Singapore. 
 
The PCR assay conditions for the housekeeping gene, GAPDH were: 94°C for 5 
min, 30 cycles of amplification (94°C for 45 sec, 60°C for 45 sec [annealing 
temperature], 72°C for 60 sec), and an additional extension step of 72°C for 5 min. 
Annealing temperatures for the other primer sets are listed in Table 2.2. The PCR 
products were separated on a 1.5% agarose gel (1st Base) containing ethidium bromide 
and then photographed under ultraviolet light. The message band intensities were 
quantified with SynGene GeneTools analysis software (Cambridge, England) and 































Table 2.2 Primer sequences for RT-PCR 
Gene Primer Sequence (5’ – 3’) Annealing 
Temp (oC) 





GTCGGTGTGAACGGA 60 380 
    
Rps27a F ACCATCACGCTCGAGGTTGA 57 333 Rps27a R AGGACACTCTCGACGAAGTC 
    
IL1β F CTG TCC AGA TGA GAG CAT  60 630 IL1β R AGGAAGACAGGCTTGTGC  
    
IL2 F AACAGCGCACCCACT  60 268 IL2 R GAGTCAAATCCAGAACATGCCGCAG 
    
IL4 F CCAGCTAGTTGTCATCCTGC 60 289 IL4 R GAGTCTCTGCAGCTCCATGA 
    
IL10 F ACTGCTATGCTGCCTGC 60 446 IL10 R CACCTTGGTCTTGGAGC  
    
IL12p40 F CAGAAGCTAACCATCTCCTGGTTTG 59 396 IL12P40 R TCCGGAGTAATTTGGTGCTTCACAC 
    
IL12p35 F CCATCGATGAGCTGATGCAG 60 164 IL12p35 R ATGCTGAGGTAGCTGTGCCA 
    
IL18 F GGCCCAGGAACAATGGCTGCC 60 155 IL18 R GGGTCACAGCCACTCCTCTTAC 
    
GMCSF F TGGCCTGGGCTTCCTCAT 60 278 GMCSF R GGATGACATGCCTGTCAC 
    
TNFα F TGCACCACCATCAAGGACTC 58 359 TNFα R CAGCTCAGCTCCGTTTTCAC 
    
IFNγ F  ACTGCCACGGCACAGTC  60 389 IFNγ R CCGCTTCCTGAGGCTG 
    
TGFβ F CTGCAAGACCATCGACAT 55 580 TGFβ R ACAAGAGCAGTGAGCGCT 
    
Xcl1 F CCATGGGTTGTGGAAGGTGT 58 294 Xcl1 R CAGTCAGGGTTATCGCTGTG 
    
Cxcl1 F CGCTCGCTTCTCTGTGCAGC 60 234 Cxcl1 R ACCAAGGGAGCTTCAGGGTC 
    
Cxcl2F GAACATCCAGAGCTTGAG 55 278 Cxcl2R AACTCTCAGACAGCGAGG 
    
Cxcl9F ATGCACAACAGCTGTCTGGC 57 370 Cxcl9R TGCCACTAAGCTACAGCCAC 
    
Cxcl10F CGTGGTCACATCAGCTGCTA 57 244 Cxcl10R TAGAACTGACGAGCCTGAGC 
    
Cxcl14F AGGACAAGGGAAGATGCAGG 58 327 Cxcl14R AACCTGCATGCAGCACTCAG 
    
Ccl2 F GCATCCACGTGTTGGCTCAG 60 383 Ccl2 R CACACTGGTCACTCCTACAG 
    





Table 2.2 Primer sequences for RT-PCR (continued) 
Gene Primer Sequence (5’ – 3’) Annealing 
Temp (oC) 
Expected Product Size 
(base pairs) 
Ccl6 F ATCCTTGTGGCTGTCCTTGG 60 268 Ccl6 R GGCACCTCTGAACTCTCC 
    
Ccl7 F TCTGTGCCTGCTGCTCATAG 60 230 Ccl7 R CCTCCTCGACCCACTTCTGA 
    
Ccl8 F ACGCAGTGCTTCTTTGCC  53.8 511 Ccl8 R GCTGCTTCTTAACTCAGGTG 
    
Ccl17F GGTCACTTCAGATGCTGCTC 60 220 Ccl17R TCTGCACAGATGAGATTGCC 
    
Ccl19 F GCCTTCAGCCTGCTGGTTCT 60 289 Ccl19 R GGCTCCTTCTGGTGCTGTTG 
    
Ccl21a F CTGGACCTGGCTCTCTGCAT 60 227 Ccl21a R ATCAGGTTCTGCACCCAGCC 
    
Ccl22 F CGTCCTTCTTGCTGTGGCAA 60 233 Ccl22 R CTTCTTCACCCAGACCTGCC 
    
Foxp3 F TCGTAGCCACCAGTACTCAG 57 386 Foxp3 R ATCTACGGTCCACACTGCTC 
    
TLR2 F TGGGTGGAGAACCTCAGCGT 60 302 TLR2 R GCCACTCCAGGTAGGTCTTG 
    
TLR5 F CGGAGAACCCAAGCTTAG  51.5 639 TLR5 R CCTTGTCCTTGAACACCA 
    
TLR9 F TGGCATGGCTACCTTTGCTG 60 600 TLR9 R CAACACCACCACGTCCTTGC 
    
Fcεr1γ F CGGAGCCAGGAGACATATGA 60 344 Fcεr1γ R TTGAGTCAGGTCTCTGGCAG 
    
Fcγr1F ACCTCCCTCAGGTCCAGATA 57 264 Fcγr1R GTGACACCCATGTAAGCCGT 
    
IL1r1 F CTCATGGTGCCTCTGCTGTC 60 529 IL1r1 R CCCTCTGTGCTCTTCAGCCA 
    
IL1r2 F GTGGTTGGCTAACAGCACGT 58 356 IL1r2 R CTGGTTGTCAGTCCGTAGCT 
    
iNOS2 F AAAGCCACGAGGCTCTGACA 58 259 iNOS2 R ACCATCACGCTCGAGGTTGA 
    








Rac1 F GTGTGTGGTGGTGGGAGACG 60 405 Rac1 R GGGTAGGTGATGGGAGTCAG 
    
Scye1 F CTCAAGCAGGTTGCTCT 60 381 Scye1 R CGATGCGTCGATAGGCTTGG 
    
MIP2 F ATGGCCCCTCCCACCTGCCG 53 383 MIP2 R TCAGTTAGCCTTGCCTTTGT 
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LGG Persistence:  
6hr, 24hr & 48hr
Figure 2.1. Schedule of experiments on normal healthy mice. To determine the 
duration in which instilled LGG can persist within the host, bladder, kidneys, draining 
lymph nodes and spleens were harvested at various time points after 1 or 6 instillations. A 
separate group of mice bladders and draining lymph nodes were harvested 6 hr after the 
5th and 6th instillation for microarray and RT-PCR analyses. Solid arrows signify 
instillation schedule; Dashed arrows signify end-point experiments.  
 
 
2.3.2.5 Optimising LGG instillation schedule  
The first group of healthy mice were instilled with live or lyo LGG once a week 
for 6 consecutive weeks as per the clinical instillation schedule for BCG immunotherapy.  
Subsequently a second instillation schedule of 2 instillations per week for 6 consecutive 
weeks was also included to determine if increased instillation frequency resulted in 








2.3.3 Orthotopic tumour model  
2.3.3.1 Tumour implantation 
MB49-PSA cells’ ability to secrete free-PSA was confirmed with commercial 
PSA chemiluminescence detection kit purchased from Autobio Diagnostics Co., LTD, 
China (protocol described in Section 2.3.3.2) before use in tumour implantation. To 
induce tumour, female C57BL/6 mice were first anaesthetized then 100 µl of 0.1mg/ml 
PLL was first instilled into the bladder and allowed to dwell for 20 min. Then 100 µl 
MB49-PSA cells (1x106cells/ml) resuspended in RPMI 1640 without L-glutamine, FBS 
or antibiotic supplementation was instilled into each mouse after squeezing out the PLL 
instilled earlier. The catheters were occluded with Combi-stoppers and the tumour cells 
were allowed to incubate in the bladder for approximately 2 hr. After the 2 hr, the 
catheters were removed. Therapy began 4 days after treatment. Table 2.3 details the 
various treatment groups.  
 
2.3.3.2 Free Prostate Specific Antigen (f-PSA) Chemiluminescence Immunoassay 
Kit 
100µl of f-PSA standards or samples (urine or bladder protein lysate) were 
dispensed into appropriate wells in duplicates. Following that 100µl of sample diluents 
(provided by manufacturer) was dispensed to all wells then sealed and mixed gently on a 
shaker for 30 sec before incubation at 37oC for 1 hr. After 1 hr, the plate was washed 5 
times with ddH2O before 200µl of enzyme conjugate (provided by manufacturer) was 
added to the wells, mixed gently on a shaker and then incubated for a further 60 min, 
37oC. During this time, equal volumes of chemiluminscence immunoassay (CLIA) 
  
50
substrates A and B were mixed and stored away from light at room temperature until 
ready to use. After incubation, the plate was washed as described earlier before 100µl the 
CLIA substrate mixture was added to each well and mixed gently for 10 sec. The plate 
was then incubated in the dark for 5 min (RT). Following that, the related light unit 
(RLU) was recorded using the Tecan plate reader (Austria). For data analysis, the values 
from sample wells were extrapolated based on the standard curve obtained. Samples that 
registered f-PSA values greater than or equal to the mean plus 3 standard deviations of 3 
independent untreated controls were considered tumour-positive.  
 
2.3.3.3 Monitoring tumour implantation efficiency and disease progression 
The mice were monitored daily for survival or terminal morbidity and were 
euthanized upon 20% weight loss or other signs of distress such as dull fur, apathy or 
visible signs of growing tumour. Euthanization was performed under anaesthesia by 
dislocation. Mice were transferred to metabolic cages a day before the scheduled 
treatment for urine collection. 100 µl Complete mini protease inhibitor cocktail tablets 
(Roche Diagnostics, Switzerland) reconstituted in 1xPBS were added to urine containers 
to prevent protein degradation. Overnight urine was collected and analysed for free-PSA 
using the free-PSA chemiluminescence kit. Only tumour-bearing mice will test positive 
for free-PSA in their urine.  
Urine free-PSA levels were normalised against urine creatinine using the 
creatinine assay kit (Wako, Japan). Briefly, urine was diluted 10-fold with double 
distilled water (ddH2O), then 300 µl deproteinising solution was added to 50 µl diluted 
urine or standards and incubated at room temperature (RT) for 10 min; the mixture was 
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then centrifuged (2,500rpm, 10 min). 200 µl colour reagent was then added to equal 
volume of supernatant and incubated (RT, 20 min). Finally, 150 µl of the mix was 
aliquoted to a 96-well plate and the absorbance at 520 nm was recorded within 30 min 
(Tecan Sunrise/ XFluor4, Austria). 
 
2.3.4 Treatment of bladder cancer 
Following tumour implantation, the animals were randomised to Control and 
Treatment groups. The day of tumour implantation was designated as Day 0. Intravesical 
therapy was started on Day 4 up to Day 39; treatment was performed every 7th day. 
Figure 2.2 illustrates the treatment and experimental schedule. 
 
2.3.4.1 Intravesical therapy with bacteria   
The lyo LGG group (n = 10 – 14; experiment repeated 5 times) was instilled with 
100 µl Lyo LGG derived from 1x108 cfu LGG once a week for 6 weeks; while the Live 
LGG group (n = 10; experiment repeated twice) was instilled 100 µl of viable LGG 
(1x109 cfu/ml). A third group of mice (O+I) (n = 10; experiment repeated twice) were fed 
108 ‘live’ LGG 1 day before their scheduled instillation of 100 µl Lyo LGG (derived 
from 1x108 cfu LGG). The intravesical live LGG dose was determined based on reports 
by Lim et al [93], where the author found that that oral feeding of  1.6 x 108 live LGG 
daily exhibited chemopreventive effects on the subcuteanous bladder tumour bearing 
mice.  
LGG efficacy was compared with the gold standard, ImmuCyst® (Bacillus 
Calmette-Guérin, substrain Connaught) (Aventis Pastuer, France). ImmuCyst® was first 
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diluted with the diluent provided and then centrifuged (4,000 rpm, 10 min). The 
Immucyst pellet was resuspended in 10 ml 1x PBS, and each mouse was instilled with 
100 µl of this Immucyst preparation (10.5 ± 8.7 x 107 cfu/ml). The Immucyst dose was 
determined based on reports by de Boer [40]. All BCG preparation and instillation work 
was carried out in a biosafety cabinet, class II. Control mice (n = 10) were instilled and/or 
fed 1xPBS in place of bacteria. Table 2.3 summarises the various treatment groups.  
 







Instilled with PBS 
Live LGG (Live) 
 
Instilled with 100 µl of live LGG (1x109cfu/ml)  
Lyo LGG (Lyo) 
 
Instilled with 100 µl of lyophilised LGG  
(6.308 ± 4.666 x 108 cfu/ml) 
Control (O+I) 
 
Mice were fed 100 µl PBS one day before PBS instillation 
Oral and intravesical LGG 
(O+I) 
Mice were fed 100 µl live LGG (1x109cfu/ml) one day 




Mice were instilled with 100 µl of BCG (10.5 ± 8.7 x 107 
cfu/ml). 
 
2.3.5 Metastasis confirmation 
Tissues that presented with gross pathology were harvested to check for 
metastasis using real-time PCR to detect for the human PSA gene. Total RNA was 
harvested from the tissues using Trizol and 5 µg total RNA was converted to cDNA using 
80 units of Superscript II RNase H- Reverse Transcriptase.  
19 µl master mix (1x TaqMan Universal PCR Master Mix [Applied Biosystems, 
USA], 1x pre-formulated target gene assay, nuclease-free water) was added to each well 
containing 1 µl cDNA (100 ng) while the 96-well standard plate was placed on ice. The 
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plate was then sealed and centrifuged (1,500 rpm, 1 min) to remove bubbles and to 
collect the contents at the bottom of the wells.  Negative ‘no template’ controls were 
included for each primer set to verify the absence of contamination and primer-dimer 
amplications. 18S rRNA was used as the endogenous control; each template was tested in 
triplicates to confirm the reproducibility of the assays.  
The PCR reaction plate was run on the Applied Biosystems 7500 Real-Time PCR 
System. The thermal cycling parameters were: 50°C for 2 min, 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 sec, 60°C for 1 min. Data was analysed using the Applied 
Biosystems 7500 Real-Time PCR System Software. Table 2.4 lists the specific probe and 
primer sets chosen from Applied Biosystems’ online pre-designed TaqMan probe and 
primer catalogue (https://products.appliedbiosystems.com/).   
Table 2.4. TaqMan® primers for metastasis detection. 
Gene  Symbol Gene Name TaqMan® Assay ID 
18s Eukaryotic 18S rRNA Hs99999901_s1 
KLK3 Prostate specific antigen; Kallikrein-related peptidase 3 Hs00426859_g1 
 
2.3.6 Analysis of TNFα, TGFβ and IL10 expression in local lymph nodes 
Total RNA was isolated from local lymph nodes of mice at end-point and 5 µg 
total RNA converted to cDNA using 80 units of Superscript II RNase H- Reverse 
Transcriptase. Real-time PCR was carried out as described above. The specific probe and 






Table 2.5 TaqMan® primers for immune response changes in local lymph nodes. 
Gene  Symbol Gene Name TaqMan® Assay ID 
IL10 Interleukin 10 Mm00439616_m1 
TNF Tumour necrosis factor Mm00443258_m1 
TGFβ1 Transforming growth factor, beta 1 Mm00441724_m1 
 
 
2.3.7 Urinary cytokines  
The amount of urinary cytokines (TNFα and IL10) were also analysed with 
commercial ELISA (BD Biosciences). Briefly, 100 µl capture antibody (Ab) diluted in 
coating buffer was added to each well, and incubated overnight (4oC). The plates were 
then washed three times with wash buffer (PBS with 0.05% v/v Tween 20, Sigma) and 
blocked with 200 µl assay diluent (RT, 1 hr). Following which, the plates were washed 3 
times before the addition of 100 µl standard or urine sample. Plates were incubated for 2 
hr at RT. The plates were washed again, then 100 µl working detector (biotinylated 
detection Ab and strepavidin-horseradish peroxidase conjugate [HRP]) was added to each 
well (RT, 1hr). The plates were then washed before 100 µl of 3, 3’, 5, 5’-
tetramethylbenzidine (TMB) substrate solution (Pierce Biotechnology Inc., USA) was 
added to each well, and incubated in the dark (RT, 30 min). 50 µl stop solution (2N 
H2SO4, Sigma) was added to each well to stop the reaction. The absorbance was read at 






2.3.8 Bladder protein isolation  
Mice bladders were resected 24 hr after the last instillation; the tissues were first 
snapped frozen in liquid nitrogen before storage at -80oC until ready for analysis. The 
bladders were homogenised on ice in 1 ml Complete Mini (Roche) mix. Following 
homogenisation, the mixture was centrifuged (12,000 rpm, 15 min) and the supernatant 
was collected for protein analysis. The amount of protein concentration was determined 
with Pierce Micro BCA Kit (Pierce Biotechnology Inc.).   
 
2.3.8.1 Analysis of cytokines in bladder post-microbe instillations  
Mice bladders were harvested 1 day after the last instillation and homogenised as 
described earlier before analysis using the Mouse Cytokine Antibody Array C Series 
1000, an antibody-based cytokine array from RayBio® (USA) which can detect 96 
mouse cytokines in single experiment.  
Briefly, 1 ‘-’ membrane and 1 ‘+’ membrane were placed in the same well in a 8-
well hybridization plate and blocked overnight (4oC) with 2ml of 1x blocking buffer. A 
2x blocking buffer stock was provided by the manufacturer. To obtain a 1x solution, the 
stock solution was diluted with ddH2O.  
After blocking, the blocking buffers were decanted before 1mg total bladder 
protein lysate was added to each membrane set (2 hr, RT). After incubation, the 
membranes were washed in 2ml of 1x Wash Buffer I (20x Wash Buffer I provided by 
manufacturer) diluted with ddH2O (3 times; 5 min per wash; with shaking). Following 
which, the memebranes were washed twice with 2ml 1x Wash Buffer II (5min per wash; 
with shaking). The ‘-’ and ‘+’ membranes were placed into separate wells from this step, 
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and 100 µl primary antibody was added to each membrane  and incubated for 2 hr at 
room temperature, and washed as before. Then 1 ml of diluted biotin-conjugated 
antibodies (800-fold dilution with 1x Blocking Buffer) was added to each membrane and 
incubated at room temperature for 2 hr. After incubation with the secondary antibody, the 
membranes were washed as described earlier before incubaton with 2 ml of 1,000 fold 
diluted HRP-conjugated streptavidin (diluted in 1x Blocking Buffer).The detection step 
was carried out within 40 min and the chemiluminescent array image was recorded on X-
ray film and the scanned TIFF image of the array was analysed with the SynGene 
GeneTools software. 
 
2.3.8.2 Confirmation of cytokine protein array data with ELISA 
Of the panel of proteins that were differentially expressed (2-fold) with respect to 
control tumour-bearing bladder, 7 proteins were selected for further analysis with 
commercially available ELISA kits. The proteins were – matrix metalloproteinase 9, pro-
form (Pro-MMP9), E-selectin, Lymphotactin, Vascular Endothelial Growth Factor D 
(VEGF-D), Vascular Endothelial Growth Factor Receptor 2 (VEGF-R2), Osteopontin 
(OPN) and TNFα. other than TNFα, which was supplied BD Pharmingen, all other kits 
used were from R&D Systems (USA). Brefly, 96-well Nunc Immuno Modules 
(Denmark) were coated with primary antibody (overnight, 4oC) and the coated plates 
were washed before adding the diluted protein samples (samples were diluted in 10% 
FBS/ PBS). Subsequent steps were performed according to manufacturer’s instructions. 
Bladder proteins from 2 healthy mice and proteins from MB49-PSA cells were also 




Mouse bladder tissues were collected 1 day after the 2nd instillation the tissues 
were fixed and sectioned. The tissue sections were collected on slides which were then 
dewaxed and hydrated in ddH2O then washed 3 times in 1x PBS (5 min per wash). 
Following this, the slides were blocked in 3% H2O2 (BDH, USA) dissolved in methanol 
(Lab-Scan Analytical Sciences, Poland) for 15 min. After blocking, the slides were 
washed then blocked again in 5% normal rabbit serum (Vector Laboratories, United 
Kingdom) for 60 mins. After incubation, the slides were washed as described earlier. The 
slides were then incubated overnight with primary antibodies (1:10 dilution); the 2 
primary antibodies used were anti-Mac-3 (BD Biosciences) and anti-neutrophil 
(Cedarlane, USA). The next day, the slides were washed before incubation with anti-rat 
IgG (1:200 dilution) (Vector Laboratories) for 1 hr. After which, the slides were washed 
again before incubation with avidin-biotin complex (Vector Laboratories) for 1 hr. The 
slides were washed 3 times in 1x PBS (5 min per wash) before a final rinse with Tris-
Buffered Saline (TBS) (1st Base). Following which the slides were incubated in 3,3'-
diaminobenzidine (DAB) solution (Sigma) for 10 mins then washed 5 times in TBS (5 
min per wash). The slides were counterstained with methyl green (Sigma) for 5 min and 
then rinsed in ddH2O. Finally the stained slides were dehydrated in alcohol, cleared in 


































Figure 2.2. Treatment schedule for the orthotopic bladder tumour model. Tumour 
was implanted on Day 0, while LGG therapy began on Day 4. Mice were terminated on 
Day 40 (1 day after the last instillation) and their bladders were harvested for protein 
analysis. A separate group of mice were harvested 1 day after the 6th instillation and their 
spleens and draining lymph nodes were harvested for specific immune cell population 
analyses by flow cytometry. A third group of mice were harvested 1 day after the 2nd 
instillation and their bladders were used to detect macrophage and granulocyte/neutrophil 
infiltration using immunohistochemical techniques. Solid arrows signify instillation 










2.4 Re-selection of the tumour cell line  
The re-selection of the tumour cell line was necessary since it was observed that 
the bladder tumours were spontaneously regressing in about 40% of the mice. Briefly, 
four C57BL/6 mice were implanted subcutaneously with MB49-PSA cells; tumour 
volume was monitored for a month. All mice bore visible tumours on their flanks one 
week after tumour implantation; 1 mouse was sacrificed, the subcutaneous tumour was 
resected and grown in vitro. Single tumour cells were derived using collagenase digestion 
described earlier. The cells were then counted and seeded in 24-well culture plates (100 
cells/well) and maintained as per MB49-PSA cells. Free-PSA secretion was monitored 
and confirmed by ELISA; colonies that did not produce free-PSA were discarded. After 1 
month in culture, 5 wells were selected for subcutaneous tumour implantation; n = 4 each 
group. Tumour volume was again monitored for 4 weeks. The colony that still bore 
subcutaneous tumours after 1 month was eventually used for subsequent orthotopic 
tumour implantation.  
 
2.5 Co-culture of LGG with mammalian cells 
Viable cells were identified using trypan blue exclusion. 1 x 105 cells were seeded 
into 6-well culture plates in either PG (RPMI complete media with Penicillin G [Sigma] 
only [5000units/ml]) or PS media and allowed to settle overnight before 1 x 108 cfu LGG 
was added to the culture well. All experiments (unless otherwise stated) had 0.2 µm 
Anopore® membranes (Nunc) or 0.4 µm polyethylene terephthalate cell culture inserts 




2.5.1 In vitro stimulation of splenocytes with live or lyo LGG  
Splenocytes were harvested as described earlier (Section 2.3.2.2); 2x106 cells/well 
splenocytes were seeded in PS media in 24-well culture dishes and allowed to settle 
overnight.  Live LGG (2x108 cfu) and lyo LGG were inoculated into the treatment wells 
the following day. Total splenocyte mRNA was harvested using Trizol 2, 4, 6, 8 and 12 
hr post-stimulation. The following Th1 - IL12p40 and TNFα, and Th2 cytokines, IL10, 
were probed using RT-PCR. IL10, IL12p40 and TNFα cytokine levels in particulate-free 
cell culture supernatants were determined by commercial capture ELISA (BD 
Biosciences).  
 
2.5.2 Effects of LGG on MB49 cell proliferation 
4 x 106 MB49 cells were stained with CalceinAM (Molecular Probes, USA). The 
reagent was reconstituted in dimethyl sulfoxide (Sigma) to a working concentraiton of 
10µm/5ml. The cells were incubated with the reconstituted reagent for 1 hr (37oC) with 
intermittent agitation before they were seeded into 6-well plates (2 x 105 cells/well) in 
either PG or PS media. The cells were allowed to settle overnight before they were 
incubated with 1x108 cfu LGG/well. After 24 and 48 hr, the cells were harvested for flow 
cytometric analysis. 
 
2.5.3 Cell cycle analysis 
1 x 105 MB49 cells were treated with 1x108 cfu LGG in either PG or PS media for 
72 hr. Cell culture inserts were used to separate bacteria from tumour cells. Following 
treatment, all cells (floating and adherent) were harvested and the cell numbers were 
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adjusted to 1 x 105/sample before they were fixed overnight in ice cold 70% v/v ethanol. 
The cell pellet was collected by centrifugation (7,500 rpm, 5 min). After the supernatant 
was removed the fixed cells were incubated (RT, 30 min) with 5 µl propidium iodide (1 
mg/ml), 10µl RNAse A (1000 Kuntz units/ml) in 500 µl sample buffer (1g/l glucose 
diluted in 1x PBS; sterile filtered). All reagents were from Sigma. The stained cells were 
then analysed by flow cytometry. The experiment was also performed on MGH cells.  
A histogram of the DNA a healthy cell population will have distinct G1 and G2-M 
phases of the cell cycle. In actively dividing cultures, the S-phase is also prominent with 
little or no cells in the sub-G1 phase. This is illustrated in Figure 2.3. If however, the 
experimental conditions lead to cell death (apoptosis and/or necrosis) the histogram 
might not be as well-defined. There would also be an accumulation in the sub-G1 cell 
population.  
 
Figure 2.3 Histogram of DNA content of healthy cells. There is minimal accumulation 





2.5.4 Nonsteroidal anti-inflammatory drugs (NSAID) activated gene (NAG-1) real-
time PCR 
NAG-1 expression in MGH cells at various time-points (24, 48 and 72 hr) was 
measured using real-time PCR. Briefly, total RNA from treated and control cells were 
isolated with Trizol reagent after which 5 µg total RNA was converted to cDNA with 
Superscript II RNase H- Reverse Transcriptase. 1 µl cDNA (100 ng/µl) was added to each 
reaction well along with 19 µl master mix (1x PCR Power SYBR® Green PCR Master 
Mix [Applied Biosystems], 1 µM forward primer, 1 µM reverse primer, nuclease-free 
water) The assay conditions used were as described earlier (Section 2.3.5). The specific 
primer sets for NAG-1 were – Forward: 5’ CGA AGA CTC CAG ATT CCG AGA G 3’; 
Reverse: 5’ CCA GCC GCA CTT CTG 3’ (1st Base). 18S rRNA was used as the 
endogenous control. The 18S primers were as follows – Forward: 5’-CGG ACC AGA 
GCG AAA GCA T-3’; Reverse: 5’-CCT CCG ACT TTC GTT CTT GAT T-3’. A 
dissociation curve analysis was performed on both primer sets to confirm primer 
sensitivity and specificity before the actual assay was performed.  
 
2.5.5 Caspase-3 activity assay 
Caspase-3 is a major protease in the apoptosis cascade; quantitative measurement 
of its activity is used to detect apoptosis in mammalian cells. For this purpose, the 
CaspACETM Assay Colorimetric System from Promega, USA was used. Briefly, MGH 
cells were seeded at a density of (0.5 x 106 cells/well) and allowed to settle overnight. 
‘Live LGG’ wells were co-incubated with live LGG (0.5 x 109 cfu/ml) the following day 
for a period of 72 hr in a humidified 5% CO2 incubator at 37oC. The apoptosis inhibitor, 
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benzyloxycarbonyl-Val-Ala-Asp (OMe) -fluoromethylketone (Z-VAD-FMK) was added 
to ‘Inhibited apoptosis’ wells (final concentration of 50 µM). Cells in the ‘negative 
control’ wells remained untreated. After 72 hr, cells were collected by centrifugation at 
1,500 rpm for 10 min at 4°C. The cell pellets were kept on ice and then washed once with 
ice-cold 1xPBS and resuspended in Cell Lysis Buffer. For ‘Live LGG’ samples, cells 
from 6 separate wells were collected as one sample and analyzed. The cells were then 
lysed by freeze-thaw method, and then incubated on ice for 15 min. The process was 
repeated 3 times to ensure complete cell lysis. The lysates were centrifuged (14,000 rpm, 
20 min, 4°C) and the supernatant fraction was collected for subsequent protein 
concentration estimation with the Pierce Micro BCA Kit.  
 Duplicate wells containing 100 µg proteins extracted from blank (no cell extract), 
negative control (extract from untreated control cells), induced apoptosis (extract from 
‘live LGG’ cells) and inhibited apoptosis (extract from induced, inhibitor-treated cells; 
i.e. Z-VAD-FMK wells) samples were prepared in 96-well plate for subsequent caspase-3 
activity assay.  2 µl of the DEVD-pNA Substrate (10mM stock) was added to all wells 
after the addition of 32 µl of the Caspase Assay Buffer. The plate was then sealed with 
Parafilm® laboratory film and incubated (37°C, 4 hr). After incubation, absorbance in the 
wells was measured at 405nm. Following that specific caspase-3 activity in the cell 







2.5.6 Electron microscopy 
Adherent cells were washed three times with cold 1xPBS and then harvested from 
the wells using Cell Dissociation Solution (Sigma), and collected in 15ml centrifuge 
tubes along with floating cells. The cells suspension was centrifuged (1,500 rpm, 5 min) 
the cell pellet was then washed with cold 1xPBS and centrifuged again before fixing with 
3% glutaraldehyde (GA) (Agar Scientific, United Kingdom) in 1xPBS, pH 7.4 for 1 hr. 
After this, the fixed cells were washed 3 times in 1xPBS before being embedded in 7% 
gelatine (Sigma) and stored at 4oC until the gelatine solidified; upon solidification, the 
block was fixed in 3% GA-PBS (4oC, 1 hr). Following fixation, the samples were 
removed and trimmed into smaller pieces of ~1mm thickness and post-fixed in osmium 
tetroxide dissolved in 1xPBS for 2 hrs. After post-fixing, the samples were washed 3 
times in 1xPBS and dehydrated (25% ethanol, 5 min; 50% ethanol, 10 min; 75% ethanol, 
10 min; 95% ethanol, 10 min; 100% ethanol 10 min). After dehydration, the samples 
were transferred to 100% acetone (Fisher Scientific, USA) for 10 min (twice with fresh 
acetone each time). The samples were incubated in ethanol-araldite (EM Sciences, USA) 
(1: 1) solution for 15 min, then overnight at room temperature in ethanol-araldite (1: 6) 
solution. The following day, the samples were incubated for 1 hr each in 100% araldite at 
40oC, 45oC, and 50 oC. Finally the samples were embedded in pure araldite (60oC for 24 
hr), then trimmed and sectioned (~80nm thick sections) with an ultramicrotome (Leica, 






2.6 Statistical analysis 
All in vitro experiments were independently replicated at least thrice, each time in 
duplicates. Combined data from the replicate experiments were subjected to a one-way 
analysis of variance followed by Bonferroni or Dunnett analysis [135] p-values less than 
0.05 were considered statistically significant. All graphical data was expressed as the 
mean ± standard deviation (SD) (unless stated otherwise) of combined data from the 
replicate experiments.  
All animal experiments were independently replicated at least twice. To ascertain 
the clinical significance of LGG therapies, mice from indepdent replicate experiments 
were pooled and subjected to the Chi-square or Fischer Exact tests. Statistical 
significance was set at p < 0.025 and 0.05 respectively. To compare survival, the Kaplan-




























3.1 Assessing the persistence and immunomodulatory effects of 
LGG 
While the specific aim of this dissertation was to determine the effects of LGG on 
bladder transitional cell carcinoma in vitro and in vivo, preliminary experiments were 
carried out to ascertain: 
1) immunogenic potential of LGG 
2) how long instilled-LGG can remain in the host and   
3) how it might subsequently activate the immune system.   
 
3.1.1 Live LGG up regulates TNFα expression in splenocytes 
The immunomodulatory properties of live LGG were confirmed with splenocytes. 
Briefly, 2x106 cells were co-cultured with 2x108 cfu LGG and total RNA was isolated for 
the analysis of TNFα transcripts. It was found that live LGG significantly increased 
TNFα expression in splenocytes from as early as 2 hr through 12 hr. The level of 
expression increased in a time-dependent manner (Figure 3.1).  The number of 
TNFα transcripts in unstimulated controls was also found to increase with time albeit 
with much less fluctuation than live LGG treated cells. This was likely due to the immune 
responses developed against the cells dying in the primary splenocytes cell culture, which 





Figure 3.1. Live LGG induces TNFα expression. Live LGG significantly elevated 
TNFα mRNA expression in splenocytes after 2, 4, 8, and 12 hr. Controls were 
unstimulated splenocytes. Gene expression was normalised with GAPDH levels. The 
experiment was performed thrice with duplicates and the data is presented as mean ± SD. 
Statistical significance was set at p < 0.05. 
 
 
3.1.2 Persistence of LGG-GFP in the bladder and other tissues after 1 and 6 
instillations 
 
LGG’s ability to persist in the bladder was explored since persistence is a 
prerequisite for the effective induction of an immune response. LGG-GFP was used to 
discriminate native lactobacilli from instilled LGG.  
C57BL/6 mice received 1 or 6 instillations (1 instillation a week) of live LGG –
GFP (1x108cfu). The bladder, local lymph nodes, kidneys and spleen were harvested at 
various time-points after the 1st and last instillation and examined for the presence of 
LGG-GFP.  6 hr after the 1st instillation of LGG-GFP, there was 1x103 - 6.67x104 cfu 
localised in the bladder. Some LGG-GFP was found in the kidneys of three of the four 
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mice (3/4) but none were found in the draining lymph nodes (LN) and spleens. All LGG-
GFP were cleared after 48 hr. After 6 instillations more LGG-GFP were localised in the 
bladder; only 1 mouse still had LGG-GFP in the bladder after 1 week (Table 3.1). All 
mice remained healthy after LGG-GFP instillations. Repeated LGG-GFP instillations 
resulted in more bacteria remaining in the bladder at 6 and 24 hr after instillation but the 
majority of mice were LGG-GFP free after 1 week. 
 
Table 3.1. Number of bacteria present in the tissues following one or 6 LGG-GFP 
instillations.   
Tissue 
1 instillation 6 instillations 




6.67 x 104 0 0 
4.21x105 - 
5x107 40 - 5000 0 -130 
LN 5 - 45 0 -5 0 70 - 1585 0 - 80 0 
Kidneys 0 - 500 0 0 2800 - 1.13x105 0 - 7x10
4
 0 -20 
Spleen 0 - 3535 0 0 45 - 1.01x106 0 - 210 0 -50 















3.1.3 Comparing the ability of LGG and BCG to stimulate cytokine and chemokine 
gene expression in the bladder 
 
As LGG-GFP persisted in the bladder for up to 6 hr at least, it was likely that it 
could induce gene expression changes in the bladder, which was then compared with the 
ability of BCG to do the same.  Mice were given weekly instillations of either LGG or 
BCG for a period of 6 weeks and harvested after the 4th, 5th and 6th (instillations). N = 6 
for each group for all instillation schedules. The 5th and 6th week samples were analysed 
on a microarray panel. The data obtained from the panel was further analysed by RT-
PCR.  
 
3.1.3.1 General observations 
All mice remained healthy throughout the duration of the experiment recording 
positive weight gain. It was observed that mice that received LGG and BCG instillations 
generally had enlarged local lymph nodes compared to controls (Figure 3.2). Swollen 
lymph nodes are the first discernable sign that the adaptive immune system is combating 




Figure 3.2 Bacteria instillations led to enlarged local lymph nodes. Representative 
pictures of lymph nodes proximal to genitourinary tract (white arrows) after live LGG 
(A) or live BCG instillations (B).  
 
3.1.3.2 Analysis of mouse inflammatory cytokines and receptors with microarray 
1 bladder was harvested from each group after the 5th and 6th instillations to study 
the mRNA profile of inflammatory cytokines, chemokines and their receptors. After 
normalisation against the GAPDH (endogenous control), only transcripts that were 
expressed with a 2-fold difference with respect to PBS control were considered genuine 
differential expressions. It was found that after 6 weeks, BCG induced the expression of 
cytokines: IL1β, IL10, IL12p35; chemokines: Ccl8, Cxcl2, Cxcl9, Cxcl14 and their 
receptors: Ccr2, Fcεr1, Fcγr1g, IL1r2 and TLR5 (Figure 3.3). In contrast LGG only 
induced the expression of Mif. After 5 weeks, Ccl8, Cxcl9, Fcγr1, IL1r2, Ccl2 and 
Cxcl13 were upregulated by BCG (Table 3.2), while live LGG instillations induced only 
Ccl2, Ccl8, Cxcl13, Fcer1 and IL1r2 with no significant difference from PBS control i.e. 




















                               
 
Figure 3.3 X-Ray images of cRNA array. Gene expression profiling of mouse bladder 
after 6 consecutive weeks of live BCG or live LGG instillations (1 instillation/ week). 1 
mouse bladder from each treatment group was harvested 6 hr after the last installation. 
Biotinylated cDNA probes synthesized from total RNA were hybridized to SuperArray 
Oligo GEArray Mouse Inflammatory Cytokines and Receptors, and mRNA abundance 
was quantified by autoradiography as described. Live BCG instillations were found to 
upregulate a total of 13 genes with at least a 2-fold difference compared to control. Live 



















Table 3.2. List of genes found upregulated on the array.  
   Fold Increase on Array 












1 NM_011333 Ccl2 NA NA 9.51 0.93 
2 NM_021443 Ccl8 9.11 NA 23.51 0.78 
3 NM_009915 Ccr2 2.21 NA NA NA 
4 NM_019568 Cxcl14 5.31 NA NA NA 
5 NM_009140 Cxcl2 16.47 NA NA NA 
6 NM_008599 Cxcl9 5.86 NA 146.29 0 
7 NM_018866 Cxcl13 NA NA 3.73 0.77 
8 NM_010185 Fcεr1g 3.97 NA 10.93 1.17 
9 NM_010186 Fcγr1 4.09 NA NA NA 
10 NM_010548 IL10 5.81 NA NA NA 
11 NM_008351 IL12a 6.68 NA NA NA 
12 NM_008361 IL1b 41.85 NA NA NA 
13 NM_010555 IL1r2 5.67 NA 12.67 1.72 
14 NM_010798 Mif 0.39 0.96 NA NA 
15 NM_016928 TLR5 50.90 NA NA NA 
‘NA’ indicates absent in sample. Cxcl9 and Fcγr1 (bold and underlined) up regulation 










3.1.3.3 Analysis of mouse inflammatory cytokines, chemokines and receptors with 
RT-PCR 
To validate the array data, semi-quantitative RT-PCR was performed on 34 genes 
of the 112 on the array. These genes included all those upregulated on the arrays as well 
as a selection of those not detected on the array and the housekeeping gene, GAPDH. 
Bladders from mice that received 4 weekly instillations were also analysed. After 6 
weeks of repeated BCG instillations there were significant upregulation of Ccl6 and 
RANTES (Ccl5), and increased Fcγr1 expression, while LGG downregulated Ccl7, Ccl8, 
IL18 and TNFα.  
At 5 weeks, BCG significantly upregulated Cxcl9 and Xcl1; LGG weakly 
upregulated Ccl2 and downregulated Ccl8, IL16 Ccl6, Ccl21a and IL18 (i.e. less than 2-
fold difference) expression at the same time. After 4 weeks, BCG significantly 
upregulated Ccl7, IL1β, Cxcl9, Cxcl10, Fcεr1 and MIP2 (Cxcl2), while LGG, 
upregulated Cxcl10, Fcεr1, IL1r2 and IL16 (Figure 3.3, Table 3.3). Both Ccl17 and 
Ccl22 (Th2 chemokines) were undetectable. BCG increased iNOS expression as early as 
the 4th instillation and it continued to do so up to the 6th week (Figure 3.4).  
That BCG induced gene expression increase after 4 or more instillations was 
confirmed by monitoring TNFα expression after 1 and 4 weeks of BCG instillations. 
TNFα was absent after 1 instillation (Figure 3.4) but induced after 4 or more instillations. 






Figure 3.4. Gene expression changes induced by the microbes. To confirm the array data cDNA was synthesized from total RNA 
isolated from the bladders of control mice (n=6) and mice instilled with live BCG (n=6) or live LGG (n=6) for 1, 4, 5 and 6 weeks. 
PCR was performed to confirm and identify gene expression changes. The following genes were found to be differentially expressed: 
IL1β, Fcεrγ1, Cxcl9, Ccl6, Ccl7, Ccl8 IL16, Fcγr1, RANTES, IL18, TNFα, Cxcl10, MIP2, iNOS and Xcl1. Gene expression was 




Table 3.3. Relative expression of chemokine genes analysed by PCR.  
 No. of Instillations 
 4 5 6 
Gene Control  Live BCG Live LGG Control  Live BCG Live LGG Control  Live BCG Live LGG 
Ccl2 - 0.17 ± 0.10* - 0.76 ±  0.69 1.28 ±  0.43 1.03 ±  0.56 0.06 ± 0.04 0.09 ± 0.06 0.04 ± 0.05 
RANTES 0.12 ± 0.01 2.20 ± 1.18 0.06 ± 0.05 0.03 ± 0.02 0.13 ± 0.06 0.02 ± 0.01 0.52 ± 0.34 1.08 ± 0.24* 0.50± 0.39 
Ccl6 0.21 ± 0.20 0.59 ± 0.25 0.24 ± 0.30 0.59 ± 0.35 0.27 ± 0.12 0.30 ± 0.25 0.24 ± 0.24 0.57 ± 0.23* 0.05 ± 0.04 
Ccl7 0.37 ± 0.31 2.21 ± 0.75* 0.45 ± 0.41 0.17 ± 0.09 0.24 ± 0.06 0.16 ± 0.07 1.52 ± 1.90 0.92 ± 0.27 0.53 ± 0.54* 
Ccl8 0.91 ± 0.21 6.43 ± 4.19 2.24 ± 2.09 1.21 ± 0.23 1.15 ± 0.40 
0.382 ± 
0.36* 2.82 ± 1.57 1.44 ± 0.84 0.36 ± 0.30* 
Ccl17 - - - - - - - - - 
Ccl21a 0.16 ± 0.11 0.12 ± 0.07 0.11 ± 0.07 0.15 ± 0.20 0.30 ± 0.30 0.05 ± 0.04 0.21 ± 0.41 0.53 ± 0.32 0.09 ± 0.15 
Ccl22 - - - - - - - - - 
Cxcl2 0.31 ± 0.11 1.44 ± 0.64* 0.27 ± 0.16 0.09 ±  0.15 0.09 ±  0.08 0.18 ±  0.22 0.38 ± 0.36 0.82 ± 0.14 0.21 ± 0.34 
Cxcl9 0.06 ± 0.05 2.29 ± 0.34* 0.08 ± 0.09 0.13 ± 0.14 1.26 ± 0.39* 0.20 ± 0.16 0.12 ± 0.09 0.59 ± 0.44 0.31± 0.38 
Cxcl10 0.61 ± 0.17 4.74 ± 2.81* 1.28 ± 1.22 0.12 ± 0.06 0.49 ± 0.26 0.09 ± 0.08 2.47 ± 1.80 1.27 ± 0.38 1.13 ± 0.45 
Fcγr1 0.09 ± 0.02 0.20 ± 0.08 0.05 ± 0.03 0.04 ± 0.02 0.11 ± 0.107 0.02 ± 0.00 0.09 ± 0.04 0.36 ± 0.21* 0.04 ± 0.02  
Fcεr1 0.56 ± 0.1 3.97 ± 2.13* 1.14 ± 0.81 0.50 ± 0.42 0.60 ± 0.46 0.10 ± 0.13 2.63 ± 1.92 1.22 ± 0.29 1.06 ± 0.58 
IL1r2 031 ± 0.069 2.5 ± 1.3 0.64 ± 1.1 1.33 ± 0.64 0.97 ± 0.57 1.01 ± 0.96 0.67 ± 0.20 0.40 ± 0.18 0.36 ± 0.30 
IL1β 0.0167 ± 0.01 0.24 ± 0.09* 0.06 ± 0.03 0.01 ± 0.01 0.03 ±0.03 0.01 ± 0.01 - - - 
IL16 0.002 0.11 ± 0.10 0.08 ± 0.05 0.28 ± 0.07 0.30 ± 0.14 0.07 ± 0.05* 0.60 ± 0.55 0.34 ± 0.19 0.35 ± 0.31 
IL18 0.42 ± 0.10 1.77 ± 1.26 0.31 ± 0.26 0.03 ± 0.02 0.04 ± 0.04 
0.005 ± 
0.003 0.38 ± 0.20 0.26 ± 0.20 0.10 ± 0.07* 
Xcl1 - 0.25±  0.28 - 0.07 ± 0.3 0.58 ± 0.25* 0.11 ± 0.08 0.03 ± 0.02 0.18 ± 0.11* 0.02 ± 0.004 
iNOS 0.04 ± 0.04 1.54 ± 0.53 0.07 ± 0.09 0.63 ± 0.13 0.95 ± 0.22 0.47 ± 0.39 0.07 ± 0.04 0.75 ± 0.33* 0.10 ± 0.10 
TNFα 
0.096 ± 
0.047 1.08 ± 0.87 0.13 ± 0.11 - 0.09 ± 0.07* 0.02 ± 0.02 0.27 ± 0.20 0.56 ± 0.19* 0.02 ± 0.00* 
Data expressed was relative to Gapdh; ‘-‘ indicates not detectable. Data is presented as mean ± SD. ‘*’ signifies p < 0.05 with respect to control 
(mice that received no instillations). 
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Cytokine mRNA expression was only detectable when using 5 µg of RNA for 
cDNA synthesis. At 6 weeks, IL2, IL12p35, IFNγ and IL10 mRNA could be detected in 
all groups but IL12p40, GMCSF and TLR5 were not detectable (Table 3.4). There was no 
change in TLR2 or 9 expressions between treated and control mice. Since live LGG 
downregulated some genes, PCR were also performed for TGFβ and Foxp3 but none of 
the groups expressed these transcripts.  
 
Table 3.4. Cytokine and TLR gene expression in mice bladders. 
 Instillations 
 6 
Gene Control  Live BCG Live LGG 
IL2 0.1 ± 0.09  0.45 ± 0.56 0.06 ± 0.08 
IL10 0.51 ± 0.14 1.01  ± 0.53 0.24  ± 0.17 
IL12p35 0.12 ± 0.21 0.66 ± 0.80 0.23 ± 0.27 
IL12p40 - - - 
GMCSF - - - 
IFNγ 0.02 ± 0.01 0.15 ± 0.19 0.05 ± 0.07 
TGFβ - - - 
Foxp3 - - - 
TLR2 0.75 ± 0.65 2.17 ± 1.70 0.81 ± 0.14 
TLR5 - - - 
TLR9 0.09 ± 0.05 0.08 ± 0.07 0.06 ± 0.02 
β-Def 1 0.05 ±0.04 0.05 ±0.05 0.10 ±0.09 
β-Def 3 - - - 







3.1.3.4 Immune cell recruitment to the local lymph nodes and bladder 
The lack of induction of chemokine or cytokine genes by live LGG did raise the 
question of whether LGG was able to attract immune cells into the bladder. Therefore 
immune cells in the bladder and draining lymph nodes were harvested and analysed by 
flow cytometry. Overall, after repeated weekly instillations there was an increase in the 
number of cells in the bladder, with BCG instilled bladders having more cells than LGG 
instilled bladders, Table 3.5. The draining lymph nodes were also slightly enlarged. Both 
live BCG and live LGG instillations increased NK cell numbers from 4 - 6 weeks in the 
bladder and lymph nodes as shown in Table 3.5. Though T cells increased in the tissues 
with time (4 - 6 weeks) this did not correlate with BCG or LGG instillations. However, 














Table 3.5. Total cell numbers in tissues and percentage of NK cells. 













Control 30.23 ± 5.7 28.96 ± 5.25 38.54 ± 8.32 
LGG 45.92 ± 6.2 24.54 ± 5.13 36.81±  3.04 










Control 1.3 ± 0.25 31.3 ± 3.0 23.02 ± 3.1 
LGG 1.1 ±  0.23 6.7 ±  1.6 50.97  ±  4.7 * 


















) Control 14.17±  3.8 141.2 ± 34.5 25.85 ± 5.08 
LGG 34.11±  9.36 265.5 ± 74.6 58.77 ± 17.9 










Control 0.91 ±  0.3 9.9  ±  2.8 22.2  ±  2.4 
LGG 0.29  ±  0.03 13.8 ±  2.8 43.97 ±  3.9 * 
BCG 0.25  ±  0.04 14.1 ±   1.1 37.82  ±  3.9 * 
Data represented as mean ± SEM where n = 6. ‘*’ denotes a significant increase in 
recruitment compared to untreated controls for that time point. 
 
Repeated instillations of live LGG or live BCG did not result in host morbidity. 
Although both are gram-positive bacteria, they differed in their capacity to invoke an 
immune response - live BCG was more immunogenic than live LGG, inducing more 
cytokines and chemokines transcripts in the mice bladders. But like BCG, live LGG did 






3.2 Modulating LGG’s immunogenicity through lyophilisation 
It was found that live LGG instillations did not markedly change cytokine and 
chemokine expression in the bladder; as such it was lyophilised with the aim of 
improving its immunogenicity.  
Lyophilisation is a dehydration process [137] typically used to preserve a 
perishable material or make the material more convenient for transport. It is the most 
common drying method for improving the stability of pharmaceuticals including those for 
parenteral administration [137, 138]. Also, lyophilised bacterial preparations are known 
to contain highly immunostimulatory cellular debris, and as such are better than whole 
live bacteria in triggering an immune response.  
 
3.2.1 Lyophilised LGG remains viable after lyophilisation  
LGG was lyophilised (lyo LGG) in batches and reconstituted before use. When 
prepared from an overnight culture of 1 – 3 x 109 cfu/ml, the reconstituted lyophilised 
preparation had 6.308 ± 4.666 x 108 cfu/ml and viability could be retained for up to 6 
weeks if the lyophilised pellet was stored at -80oC.  
 
3.2.2 Live and Lyo LGG stimulate cytokine mRNA and protein expressions 
The immunogenicity of live and lyo LGG was determined by comparing their 
ability to stimulate splenocytes to produce cytokines. Briefly the splenocytes were co-
cultured with live or lyo LGG and total RNA was isolated for semi-quantitative PCR 
analysis on TNFα, IL12p40 and IL10 - TNFα and IL12p40 were representative Th1 
cytokines while IL10 was synonymous with Th2 immune responses.   
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Like live LGG, lyo LGG was also able to induce TNFα expression within 6 hr of 
exposure (Figure 3.5), but the latter was more effective in doing so. Similarly IL12p40 
expression was increased (Figure 3.5).  


























Figure 3.5. Effect of live and lyo LGG on splenocyte TNFα and IL12p40 mRNA 
expression. Lyo LGG significantly elevated TNFα and IL12p40 mRNA expression in 
splenocytes within 6 hr (*p <0.05 compared to unstimulated controls); in comparison to 
the results observed earlier, Lyo LGG was more potent than live LGG in inducing TNFα 
and IL12p40 transcripts. The experiment was done twice each with triplicates 






The increase in ΤΝFα and IL12p40 mRNA corresponded to the increase in both 
TNFα and IL12p40 proteins. Lyo LGG was more potent than live LGG in stimulating 
TNFα and IL12p40 (Th1 cytokines) production in splenocytes. Control unstimulated 
splenocytes constitutively secreted TNFα up to 72 hr. Live LGG stimulated significantly 
more TNFα after 6 hr but thereafter production was comparable to controls In contrast, 
lyo LGG steadily increased TNFα production up to 72 hr (Figure 3.6).  
IL12p40 levels increased after 24 hr for all 3 treatments but declined thereafter, 
however, IL12p40 production by lyo LGG remained significantly higher than control 
(Figure 3.5). Both live and lyo LGG could also induce IL10, a Th2 cytokine. While IL10 
levels were comparable in control and live LGG wells, lyo LGG induced significantly 





Figure 3.6. Cytokine production by splenocytes stimulated with live and lyo LGG. 
While the controls (unstimulated splenocytes) constitutively expressed the cytokines, live 
and lyo LGG induced greater production at specific time points. However, lyo LGG was 
consistently more effective than live LGG in stimulating the production of TNFα, 
IL12p40 and IL10 in vitro (*p < 0.05 with respect to control). The experiment was 
performed twice with triplicates; data is expressed as mean ± SD. 
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3.2.3 Lyo LGG instillations did not result in host morbidity or mortality 
To ensure Lyo LGG was safe for intravesical instillations and to monitor the 
tolerance of animals to different instillation schedules, 2 groups of mice were instilled 
with lyo LGG for either 1) once a week for 6 weeks or 2) twice a week for 6 weeks (n = 
10 per group).  
All mice remained healthy with constant weight gain with no mortalities 
throughout the 6 week experiment even when 2 lyo LGG instillations were administered 
in a week. Also, lyo LGG instillations did not result in severe inflammation and all the 
mice received all scheduled instillations.  
 
3.2.4 Effect of one or 2 Lyo GG instillations a week on gene expression in the 
bladder 
 
The cytokine induction kinetics of lyo LGG in vivo was compared to the gene 
expression changes observed in mice that received 1 instillation of live LGG or BCG a 
week for a period of 6 weeks.  
Using SuperArray GeArray, it was found that more cytokine and chemokine 
mRNA were upregulated in the bladder when mice received Lyo LGG instillations; Lyo 







Table 3.6. List of genes found upregulated by SuperArray.  
    Fold Increase On Array 
    








Control LGG vs. Control 
1 NM_011888 Ccl19 NA NA 20.77 
2 NM_011333 Ccl2 0.41 1.44 4.07 
3 NM_011335 Ccl21a NA 2.47 NA 
4 NM_008176 Cxcl1 NA NA 21.56 
5 NM_019568 Cxcl14 NA NA 5.58 
6 NM_009140 Cxcl2 NA NA 18.09 
7 NM_019568 Cxcl4 NA 2.95 3.56 
8 NM_010185 Fcer1g 0.32 1.65 2.57 
9 NM_008351 IL12a NA NA 4.42 
10 NM_008360 IL18 NA 2.37 2.68 
11 NM_008361 IL1β NA NA 12.86 
12 NM_010555 IL1r2 0.17 1.43 4.08 
13 NM_009007 Rac1 NA 3.49 2.63 
14 NM_007926 Scye1 NA NA 6.33 
‘NA’ indicates absent in sample. IL12a (IL12p35) (bold and underlined) upregulation in 
mice that received 2 instillations per week was confirmed with PCR. Control mice were 
instilled with PBS instead of BCG or LGG. 
 
To corroborate the array data, RT-PCR was performed on all but Cxcl4. At the 
same time, RT-PCR was performed for β-defensins 1 and 3 to determine the innate 
immune responses after lyo LGG instillations since β-defensins are the body’s first line 
of defense against microbial infections and they are produced mostly by epithelia lining 
exposed surfaces.  
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Lyo LGG elevated TNFα and iNOS expression in the bladders of mice that 
received one instillation a week, while IL12p35 was significantly upregulated in mice 
that received 2 lyo LGG instillations a week (Figure 3.7). While the transcripts could be 
detected for all other genes, their expressions were comparable with control mice after 
















Figure 3.7. 2 instillations/week induced more cytokine/ chemokine mRNA than 1 
instillation/week. Semi-quantitative RT-PCR was done to corroborate the genes found to 
be upregulated by the array. Specific gene expression in the bladders of mice that 
received twice weekly instillations of lyo LGG (A). IL12p35 was significantly 
upregulated in mice that received 2 lyo LGG instillations a week (B). Control mice (n =4) 
received weekly PBS instillations.
2 instillations/ week 
  β-Def1 
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3.2.5 Lyo LGG instillations attract activated and mature dendritic cells to the 
bladder  
 
While attempts were made to characterise cytokine and chemokine changes in the 
bladder post-LGG instillation data from the microarray was inconclusive. As such, flow 
cytometry was carried out to analyse immune cells as a measure of the immune response 
in the bladder and lymph nodes after LGG instillations. 
It was found that both lyo LGG instillation schedules resulted in significantly 
more CD11c+CD83+ (activated) and CD11c+CD86+ (mature) dendritic cells (DCs) in the 
bladders (p < 0.05 compared to control); mice that received 2 lyo LGG instillations a 
week had more of both DC populations and CD8+ T-cells in their bladders (p < 0.05) than 
mcie that received 1 instillation a week. The difference could be attributable to the 
presence of more lyo LGG associated antigens in the bladder as a result of increased 
instillation frequency. Table 3.7 summarises the percentage of each specific immune cell 
population in the bladder following lyo LGG instillations; a total of 104 cells were 
anlaysed for each sample. 
 
    Table 3.7. Bladder immune cell populations after lyo LGG instillations.  
Control Lyo LGG Control Lyo LGG
CD3+CD4+ 4.533 ± 2.376 2.238 ± 1.839 9.14 ± 1.996 11.3 ± 2.81
CD3+CD8a+ 3.633 ± 1.442 4.912 ± 4.332 9.287 ± 1.735 12.82 ± 2.632*
CD11c+CD83+ 0.7817 ± 0.5837 5.743 ± 3.369* 10.41 ± 2.045 20.34 ± 7.322*
CD11c+CD86+ 0.5767 ± 0.1994 3.65 ± 2.324* 7.572 ± 1.536 14.21 ± 2.428*
Mac3+ 42.16 ± 6.118 40.53 ± 10.62 53.16 ± 8.238 41.3 ± 7.742*
pan-NK+ 24.63 ± 11.63 27.75 ± 6.065 39.2 ± 9.083 33.09 ± 6.682
B220+ 27.09 ± 7.186 37 ± 9.131 28.68 ± 14.37 25.75 ± 2.47
1 instillation/ week 2 instillation/ weekBladder
 
n = 6 per group Data is presented as mean percentage ±SD of specific immune cell 
population. A total of 104 cells was analysed for each sample. ‘*’ denotes p < 0.05 
compared to PBS control.  
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3.2.6 Lyo LGG instillations changed the immune cell population of the local lymph 
nodes.  
 
Immune cell populations in the draining lymph nodes were also characterised and 
it was found that mice receiving once weekly lyo LGG instillations had significantly 
fewer CD11c+CD83+ (actiavated) and CD11c+CD86+ (mature) DCs, but more B220+ B 
cells in their lymph nodes ( p < 0.05 compared to control). It was separately observed that 
mice receiving twice weekly instillations had fewer CD11c+CD86+  DCs, pan-NK+ and 
Mac-3+ cells in their lymph nodes. Table 3.8 summarises the percentage of each specific 
immune cell population in the bladder following lyo LGG instillations; a total of 104 cells 
were anlaysed for each sample. 
  
Table 3.8 Immune cell populations in lymph nodes after lyo LGG instillations.  
Control Lyo LGG Control Lyo LGG
CD3+CD4+ 29.19 ± 5.599 25.21 ± 6.599 19.28 ± 8.992 12.25 ± 6.496
CD3+CD8a+ 40.44 ± 15.93 28.64 ± 12.09 19.76 ± 13.65 9.372 ± 3.791
CD11c+CD83+ 5.652 ± 3.787 0.1933 ± 0.1305* 12.81 ± 7.047 5.633 ± 3.602
CD11c+CD86+ 3.455 ± 2.815 0.33 ± 0.3939* 4.193 ± 2.486 1.488 ± 0.6801*
Mac3+ 22.64 ± 4.619 27.33 ± 13.87 41.95 ± 13.17 17.22 ± 4.643*
pan-NK+ 26.43 ± 8.868 20.41 ± 12.52 5.012 ± 2.531 2.528 ± 0.703*
B220+ 43.59 ± 8.214 69.93 ± 12.42* 57.81 ± 14.82 63.37 ± 14.62
Local Lymph 
Nodes
1 instillation/ week 2 instillation/ week
 
n = 6 per group; Data is presented as mean percentage ±SD of specific immune cell 
population. A total of 104 cells was analysed for each sample. ‘*’ denotes p < 0.05 with 






It was found that lyo LGG was more efficacious than live LGG in inducing TNFα 
and IL12p40, both of which are Th1 cytokines pivotal in initiating immune responses, 
indicating that lyophilisation did indeed augment LGG’s immunogenicity. At the same 
time that Lactobacillus species are potent inducers of Th1 cytokines, they can also induce 
Th2 cytokines [58], hence accounting for the elevated IL10 in the supernatant.  
At the same time, lyo LGG instillations were safe at all applied concentrations, 1 
or 2 instillations/ week, with no host morbidities or mortality. Both instillation schedules 
were equally effective at inducing bladder dendritic cell activation and maturation (as 
signified by increased number of cells expressing the activation [CD83] and maturation 
[CD86] markers), but differed in their abilities to influence CD8+ T-cell and macrophage 
populations. The high bladder DC numbers correspond to a decrease in lymph node DCs, 











3.3 Assessing and evaluating the anti-tumour efficacy of LGG in 
vivo 
The ultimate aim of testing the safety of LGG instillations was to explore its 
capacity as an immunotherapeutic agent to treat cancer of the bladder. The PLL technique 
with MB49-PSA cells was used to produce bladder tumours in mice. Coating the bladder 
wall first with PLL ensures high implantation efficiency [113]. In addition, the PSA-
modified MB49 cell line, which actively secretes PSA, also allows non-invasive 




Figure 3.8 H&E staining of a section of a tumour-bearing bladder. Poly-L-Lysine 









3.3.1 Monitoring orthotopic tumour implantation and disease progression 
The mice were randomised to 5 treatment groups summarised in Table 3.9. 
Therapy began 4 days after tumour implantation and was given once weekly for 6 weeks. 
Since both once and twice a week LGG instillations were able to induce resident bladder 
dendritic cell activation and maturation, which is important since mature dendritic cells 
have the potential to break tumour tolerance and induce tumour-specific immune 
responses leading to tumour rejection [139], the former schedule was used as it was 
economically and clinically more viable. Mice were sacrificed 1 day after the 6th (last) 
instillation.  
 
Table 3.9. Summary of experimental groups. 
Group Treatment 
Control (C) Instilled with PBS 
 
Live LGG (Live) 
 
Instilled with 100µl of live LGG (1x109cfu/ml) 
Lyo LGG (Lyo) Instilled with 100µl of lyophilised LGG  




Mice were fed 100µl PBS one day before PBS instillation 
Oral and intravesical LGG 
(O+I) 
Mice were fed 100µl live LGG (1x109cfu/ml) one day 
before their scheduled lyo LGG instillation 
 
Apart from testing the treatment efficacies of live and lyo LGG instillations, 
another group of mice were fed 100µl live LGG (1x109cfu/ml) in addition to weekly lyo 
LGG instillations. This was coined the (O+I) group and was included to determine the 




3.3.2 General Observations  
100% tumour implantation was achieved with the PLL-MB49-PSA method 
described in Section 2.3.3.1. All mice presented with gross haematuria by Day 7, which 
was indicative of tumour presence. Only mice bearing bladder tumour will test positive 
for free-PSA in urine – all mice were PSA positive on Day 11. The urine free-
PSA/creatinine values ranged from 65.05 – 622.84 ng/ml. While urine was collected from 
as early as Days 4 and 7, free-PSA could not always be detected. Also, bladder, spleen 
and lymph node weights measured at end point did not correlate with tumour presence 
(data not shown).  
 
3.3.3 LGG instillations conferred survival advantage 
All 3 forms of LGG therapy conferred a 30% survival advantage over PBS 
controls (p < 0.05) (Figure 3.9).   
 
Figure 3.9 Kaplan Meier analysis of LGG therapy on the survival of tumour-
bearing mice. Mice receiving any of the 3 LGG therapies survived longer than PBS 
controls. Surviving mice were terminated at day 40 – 1 day after the 6th instillation. 
Experiments with live and O+I groups were performed twice (n = 10 each time). Lyo 
experiment was performed 4 times (n = 10 – 15 each experiment).  
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3.3.4 LGG therapy conferred protective effect over PBS 
All 3 forms of LGG therapy rendered a protective effect over PBS.  Up 60% of 
controls bore bladder tumours as confirmed visually, and with free PSA-ELISA, 
compared with ~30% in the LGG groups (Table 3.10). Complete tumour regression as 
characterised by no urine free-PSA typically occurred after the 2nd and 3rd LGG therapies.  
 
Table 3.10. Odds ratio (OR) of having bladder cancer with LGG treatment.   
Group % Cancer Sample Size OR 95% Confidence 
Interval 
p-value 
Control 61.9 37 1 - - 
Live LGG 31.6 19 0.195 0.059 – 0.646 0.006* 
Lyo LGG 39.5 43 0.277 0.109 – 0.703 0.006* 
Control (O+I) 60 5 1 - - 
O+I 35 20 0.359 0.048 – 2.683 0.358Ω 
Chi-square test was used for comparisons between control (PBS mice), live and lyo LGG. 
Statistical significance was set at p < 0.025. Fisher’s Exact test was used to compare 
between C(O+I) and O+I. ‘O+I’ is defined as mice fed live LGG orally one day before 
lyo LGG instillation. ‘*’ signifies p < 0.05 with respect to ‘Control’; ‘Ω’ signifies p < 0.05 
compared to ‘Control (O+I)’.  
 
 
3.3.5 Elucidating LGG’s anti-tumour mechanisms 
3.3.5.1 Analysis of bladder proteins post-LGG therapy 
The presence of LGG and/or tumour may alter the cytokine levels, as such 
bladder proteins were harvested and analysed using a cytokine antibody array, which 
consisted of 2 membranes (array 4.1 and 3.1) blotted with antibodies detecting a total of 
96 cytokines.  
3 bladders each with different pathologies were analysed – 1) Control tumour-
bearing bladder (C-Tum), 2) Lyo LGG-instilled, tumour-bearing bladder (Lyo LGG-
Tum), and 3) Lyo LGG-instilled cured bladder. The relative protein expression levels 
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were determined by densitometry. After background elimination and normalisation 
against positive controls, a total of 18 proteins in total were found to be differentially 
expressed (2-fold or more) with respect to control tumour-bearing samples and are 
summarised in Tables 3.11 (Array 3.1) and 3.12 (Array 4.1).  
Briefly, the following proteins were detected on Array 3.1: Eotaxin-2, Interleukin 
3 receptor beta (IL3Rb), LPS induced C-X-C chemokine (LIX), Lymphotactin, 
Macrophage inflammatory protein 2 (MIP2), Platelet factor 4 (PF4), P-Selectin, Soluble 
tumour necrosis factor receptor inhibitor I (sTNF RI) and Vascular cell adhesion 
molecule 1 (VCAM1). Lyo LGG-cured sample had expressed more of these proteins than 
Control- or Lyo LGG-tumour bearing samples.  
On Array 4.1, Osteopontin  (OPN), Vascular endothelial growth factor receptor 
2 (VEGF-R2), VEGF-R3, Vascular endothelial growth factor (VEGF-D) were found only 
in the control tumour-bearing bladder; Matrix metalloproteinase 9 (pro-form) (Pro-
MMP9) were found specifically in tumour-bearing bladders; E-selectin and Fc gamma 
receptor 2B (Fcg RIIB) were found only in lyo LGG-cured bladder. While Intracellular 
adhesion molecule 1 (ICAM-1) and Thymus chemokine 1 (Ck-1) were found in all three 
groups, lyo LGG-cured and control tumour-bearing bladder had the most ICAM-1 and 











Table 3.11. Array 3.1 - Proteins found to be expressed with a 2-fold difference with 
respect to Control tumour-bearing mice.   
Array 3.1 
 






Eotaxin-2 Eotaxin-2 0.021 0.035 0.363 
IL3Rb Interleukin 3 receptor beta 0.021 0.029 0.129 
LIX LPS induced C-X-C chemokine 0.071 0.059 0.633 
Xcl 1 Lymphotactin 
 
0.045 0.065 0.415 
MIP2 Macrophage inflammatory protein 2 
 
0.070 0.070 0.141 
PF4 Platelet factor 4 
 
0.064 0.116 0.174 
P-Selectin P-Selectin 
 
0.091 0.365 0.660 
sTNF RI 
Soluble tumour necrosis factor receptor 
inhibitor I 
 
0.199 0.186 0.383 
VCAM1 Vascular cell adhesion molecule 1 0.088 0.061 0.536 
 ‘C-Tum’ and ‘Lyo LGG-Tum’ denote tumour-bearing mice in control and lyo LGG 

















Table 3.12. Array 4.1 - Proteins found to be expressed with a 2-fold difference with 
respect to Control tumour-bearing mice.   
Array 4.1  










Fc gamma receptor 2B 0.0317 0.0141 0.0620 
ICAM-1 Intracellular adhesion molecule 1  0.0706 0.0707 0.1910 
OPN Osteopontin  0.250 0.022 0.0374 
Pro-MMP-9 Matrix metalloproteinase 9 (pro-form)  0.4554 0.2056 0.0280 
Thymus 
Ck-1 Thymus chemokine 1 0.6338 0.2907 0.1377 
VEGF-R2 
Vascular endothelial growth factor receptor 
2  0.1653 0.0155 0.0275 
VEGF R3 
Vascular endothelial growth factor receptor 
3  0.0573 0.0191 0.0328 










Figure 3.10 X-ray images of Arrays 4.1. (Row A) and 3.1 (Row B). Bladders were harvested 1 day after the 6th instillation and total 
proteins were isolated for analysis with the RayBio Mouse Cytokine Antibody Array C Series 1000. Lyo LGG-cured bladder was 
found to express more chemoattractants than tumour-bearing bladders. While PBS control tumour-bearing bladders had more pro-
angiogenic and pro-metastatis proteins. Proteins expressed with a 2-fold difference with respect to control tumour-bearing bladder are 
circled.  
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In summary, lyo LGG-cured bladder had mainly chemokines that are involved in 
immune cell chemotaxis, while control tumour-bearing bladder expressed more proteins 
involved in blood vessel growth, tumour invasion and angiogenesis.  
 
3.3.5.2 Bladder protein ELISA 
Based on the array data, commercial ELISAs was performed on OPN, Pro-
MMP9, E-selectin, VEGF-R2, VEGF-D, Lymphotactin and TNFα. These cytokines were 
shortlisted for verification as they are pivotal in tumour angiogenesis [140], cancer 
metastasis [141], inflammation and their capacity to augment anti-tumour responses [142, 
143]. 
In addition to C-Tum, Lyo LGG-Tum and Lyo LGG-cured mice, total bladder 
proteins were also isolated from the other treatment groups, namely live LGG and oral 
and intravesical therapies (O+I). These along with healthy bladders and MB49-PSA cells 
were included to compare how the different LGG therapies may have altered the bladder 
microenvironment.  
Using 50µg protein, it was found that the tumour cell line, MB49-PSA 
constitutively produced E-selectin, OPN, Pro-MMP9, VEGF-R2, VEGF-D, 
Lymphotactin and TNFα. Lymphotactin, VEGF-D, VEGF-R2 and TNFα were produced 
at low levels, but E-selectin and OPN were expressed at high levels, 4318.6 and 2208 
pg/ml respectively (Table 3.13).  Healthy bladders were also found to express these 
proteins at basal levels, at amounts lower than in tumour-bearing mice.  
Of the 7 proteins analysed, all but E-selectin and VEGF-R2 expressions in C-tum, 
Lyo LGG-tum and Lyo LGG-cured reflected the same expression profiles as found by the 
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protein array. Overall tumour-bearing bladders had more OPN, Pro-MMP9 (p < 0.05) and 
E-selectin (p < 0.05) than cured bladders irrespective of the treatment administered.  
Analysing all 3 LGG groups collectively, it was found that LGG intravesical 
therapy in general significantly elevated Lymphotactin in the bladder. Oral LGG therapy 
in addition to lyo LGG instillations lowered Pro-MMP9 and OPN to levels comparable to 
a healthy bladder; OPN was also found in lesser quantities in Lyo LGG-cured bladders. 
These data indicated that lyo LGG installations reduced the amount of pro-metastatic 
proteins circulating in the bladder. At the same time, VEGF-D expression was 
significantly higher in the healthy bladders and in O+I (tumour-bearing and cured) mice 
than control tumour-bearing bladders. There was however, no linear increase in its 
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-Tum and -Cured refer to tumour-bearing bladders and cured bladders respectively. All data expressed as mean ± SD; ‘*’ denotes p < 
0.05 compared to C-tum; ‘Ω’ denotes p < 0.05 with respect to Healthy bladder.
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3.3.5.3 Profiling systemic and local immune response post-LGG therapy 
Both spleens and draining lymph nodes proximal to the urinary tract were 
harvested 1 day after 6 weekly LGG instillations for immune phenotyping using flow 
cytometry so as to determine the immune response changes following LGG therapy. Lyo 
LGG mice had fewer splenic CD3+CD8+ T-cells (Table 3.14), while mice that received 
intravesical and oral LGG therapy (O+I) had fewer splenic macrophages and NK cells 
compared to their respective controls (Table 3.14). Analysis was also performed for 
splenic and LN CD4+ and CD8+ T-cells, Ly6G+ (granulocytes or neutrophils), B-cells 
(CD19+), macrophages and NK cells, but there were no significant changes in these cell 
populations. Table 3.14 summarises the percentage of each specific immune cell 
population (mean ± SD) in the spleen following LGG therapy; a total of 104 cells were 
anlaysed for each sample. 
 
Table 3.14. Immune cell populations in spleen after various LGG therapies. 
Spleen  
Treatment CD3+CD8+ Mac-3+ pan-NK+ 
Control 20.94 ± 4.518 23.73 ± 18.72 5.162 ± 2.751 
Live LGG 20.08 ± 3.254 33.45 ± 22.94 6.352 ± 4.266 
Lyo LGG 15.99 ± 3.304* 24.18 ± 21.1 6.898 ± 3.951 
C(O+I) 21.36 ± 9.076 33.52 ± 31.21 5.51 ± 2.51 
O+I 16.04 ± 2.473 3.55 ± 1.981Φ 3.233 ± 0.9103Φ 
Control mice were instilled with PBS, Live and Lyo mice were instilled with live and 
lyophilised LGG respectively (n = 10 each). O+I mice were fed live LGG orally one day 
before instillation with lyophilised LGG; C(O+I) were fed and instilled with PBS (n = 5 
each). ‘*’ denotes p < 0.05 with respect to control, ‘Φ' denotes p < 0.05 with respect to 
C(O+I). Data is presented as mean percentage ±SD of specific immune cell population.  . 




3.3.5.4 Immune cell population in the local lymph nodes after LGG therapy 
 
Separating tumour-bearing from cured mice, lymph nodes from cured mice in the 
control group appeared normal and generally did not yield enough cells for flow analysis. 
In contrast mice that received LGG instillations had enlarged lymph nodes and 
significantly more cells. It could thus be inferred that LGG instillations led to an influx 
and/ or proliferation of immune cells in the local lymph nodes.  
Control and lyo LGG cured mice had significantly fewer splenic macrophages 
compared to control tumour-bearing mice (C-Tum) (Table 3.15). At the same time, lyo 
LGG cured mice had significantly fewer CD19+ B-cells and Ly6G+ (granulocuytes or 
neutrophils) cells in their lymph nodes than C-Tum mice (Table 3.15). While CD4+ and 
CD8+ T-cells, Ly6G, B-cells, macrophages and NK numbers were also analysed there 
were no significant changes in these populations. Analysis was not performed on lymph 
nodes from O+I mice. Table 3.15 summarises the percentage of each specific immune 
cell population in the spleen and neighbouring lymoh nodes following LGG therapy; a 












Table 3.15. Comparisons in Mac-3+, CD19+ and Ly6G+ cell populations between 
cured and tumour-bearing mice. 
Treatment 
Spleen Local Lymph Nodes 
Mac-3+ CD19+ Ly6G+ 
C-Tum 33.01 ± 22.89 76.62 ± 11.46 41.41 ± 19.04 
C-Cured 14.44 ± 6.99* 41.15 ± 14.67 8.46 ± 8.514 
Live-Tum 51.48 ± 29.61 50.97 ± 23.95 43.57 ± 36.11 
Live-Cured 25.72 ± 16.72 67.06 ± 8.208 24.33 ± 15.1 
Lyo-Tum 40.56 ± 23.37 60.3 ± 26.4 38.9 ± 22.18 
Lyo-Cured 13.26 ± 10.74* 40.05 ± 19.7* 7.665 ± 8.709* 
* denotes p < 0.05with respect to control tumour-bearing mice (C-Tum). Mac-3, CD19 
and Ly6 are macrophage, B-cell and granulocytes or neutrophils markers respectively. 
Data is presented as mean percentage ±SD of specific immune cell population. A total of 
104 cells was analysed for each sample. 
 
 
3.3.6 Histopathological and immunohistochemical analysis of Control PBS and lyo 
LGG-instilled bladders  
 
The fall in Ly6G+ cells (granulocytes or neutrophils) and macrophages in lyo 
LGG-cured local lymph nodes suggested that lyo LGG instillations led to the exodus of 
these cells from the local lymph nodes to neighnouring tissues. Hematoxylin and eosin (H 
& E) staining along with immunohistochemistry (IHC) was carried on bladders after 2 
lyo LGG instillations (1 instillation a week) to determine if the cells had been recruited 
there as a result of lyo LGG instillations since LGG mice were typically cured of bladder 






3.3.6.1 Histopathology and immunohistochemistry  
Histopathology is a powerful tool that enables the documentation of 
morphological and pathological changes during disease development and therapy. At 2 
weeks, all samples presented with bladder tumours. The tumours were confined to the 
transitional epithelium with extension into the lamina propria characteristic of 
transisitional cell carcinoma (Figure 3.11A). Inflammatory infiltrates were observed in 
and around the tumours in both PBS control and lyo LGG samples (Figure 3.11B).  
  
Figure 3.11. Representative H& E tissue sections of tumour-bearing bladders. Panel 
A shows the gross anatomy and histology of bladders of a mouse bladder tumour arising 
from PLL-MB49-PSA tumour implantation (20x magnification). Representative picture 
of Lyo LGG-treated tumour with infiltrating immune cells at high magnification (600x, 














3.3.6.2 Lyo LGG mobilised large numbers of neutrohpils and macrophages into the 
tumour 
 
Immunohistochemistry was used as an adjunct to H & E to characterise and 
ascertain the distribution and localisation of the inflammatory infiltrates.  
 
In mice that received lyo LGG, there was a heavy infiltration of Ly6G+ cells into 
the bladder tumours (Figure 3.12B) - 10 - 80% (n = 5) of tumours were infiltrated with 
these cells. The Ly6G+ cells were likely to be neutrohpils since they are the first immune 
cells to arrive at sites of infection [26]. On the contrary, only 0 – 50% (n = 5) infiltration 




















Figure 3.11 Representative images of lyo LGG and control bladder sections stained 
with antimouse neutrophil mAb. There were consistently more neutrophils (stained 
brown and/ or boxed) within tumours of lyo LGG mice (B) than PBS control mice (40x 
magnification). Panels C and D are representative high magnification photos of control 






At the same time, it was observed that Mac-3+ cells were either absent in controls 
or distributed randomly and sparsely (Figure 3.13). In contrast, receiving lyo LGG 
therapy led to an influx of Mac-3+ cells into and along the periphery of tumours (Figure 
3.13).    
 
Figure 3.13 Photomicrographs of bladder sections stained with antimouse Mac-3 
mAb (macrophage). There were more Mac-3+ cells (stained brown/ arrows) distributed 
within of lyo LGG mouse (B) than PBS control (A) (40x maginifcation). Panels C and D 
are representative high magnification (400x magnification) images of Control (C) and 




Both live and lyo LGG exhibited anti-tumour effects while conferring a 30% 
survival advantage over PBS controls. At the same time, oral therapy did not further 
augment the anti-tumour effects of lyo LGG instillations. It was also established that 
LGG therapy could influence both local and systemic immune responses as marked by 
the changes in Ly6G+, Mac-3+ and CD3+CD8+ cell populations in the local lymph nodes 
and spleen. While 6 weekly LGG instillations significantly elevated Lymphotactin, 
(lymphocyte chemoattractant) in the bladder, macrophages and neutrophils could be 














3.4 Comparing the efficacy of lyophilised LGG as an 
immunotherapeutic with BCG 
Since all 3 forms of LGG therapies were equally effective in eliminating bladder 
cancer, for ease of preparation and strain consistency, lyo LGG was used in subsequent 
comparison with lyophilised BCG.  
 
3.4.1 Re-selection of tumour cell line  
In the previous experiments it was found that the bladder tumours were 
spontaneously regressing in about 40% of untreated mice by week 4. The spontaneous 
regression was likely due to the host mounting an immune response against the tumours, 
which are themselves immunogenic. This is especially true with the MB49-PSA bladder 
tumour cells because the parental MB49 tumour cell line originated from a carcinogen-
induced tumour of bladder epithelial origin from C57BL/6 male mice [144] and as such 
the tumour cells may present a small number of HY antigens on their surface, rendering 
the MB49-PSA cells more immunogenic and in turn resulting in spontaneous regression.  
To circumvent the problem of spontaneous regression, a more tumourigenic 
MB49-PSA cell line was selected. Briefly, four C57BL/6 mice were subcutaneously 
implanted, after 1 week, all 4 mice had visible tumours on their flanks and 1 mouse was 
sacrificed; the tumour was harvested and grown in culture and selected based on free-
PSA secretion. The free-PSA concentration is summarised in Table 3.16. Eventually, 5 




Table 3.16. PSA concentration of the 5 colonies selected for subcutaneous tumour 
implantation. 








Tumour volume was again monitored for 4 weeks to ensure the tumours did not 
regress spontaneously (Figure 3.14).At the end of experiment, only mice implanted with 
cells from colony 11 still bore subcutaneous tumours. Hence colony 11 was used for 
subsequent orthotopic experiments. 
 
 
Figure 3.14Monitoring the growth of subcutaneous tumour. At the end of 4 weeks, 
only colony 11 had all 4 mice still bearing a tumour. Data is presented as mean ± SD; n = 





3.4.2 A comparison of treatment efficacy between BCG Immucyst and lyo LGG 
The efficacy of intravesical lyophilised BCG (Immucyst) therapy in murine 
bladder cancer had been demonstrated in several investigations. To confirm the treatment 
protocol was as efficacious as Immucyst, a further set of experiments were performed to 
compare the cure rates between Immucyst and lyo LGG.  
 
3.4.2.1 General observations of Immucyst-treated mice 
 
Using MB49-PSA cells that were re-selected (Colony 11), it was found that all 
mice had detectable free-PSA in their urine by Day 7, i.e. all mice had bladder tumours at 
the start of therapy. In order for urine to be collected, Immucyst mice would be placed in 
open metabolic cages where airflow could not be controlled or purified, and hence posed 
a potential harzard to workers and researchers in the vicinity. As such urine from the 
Immucyst group was not collected subsequently as advised by the NUS Institutional 
Animal Care and Use Committee IACUC. 
Severe inflammation was observed in 4/15 mice by the 3rd week of Immucyst 
therapy, resulting in failure for successful Immucyst instillation. However, therapy was 
restored after 1 week’s rest. In contrast, neither the controls nor lyo LGG mice presented 
with the same pathogenesis.  
 
3.4.2.2 Lyo LGG is as efficacious as Immucyst in treating bladder cancer  
Lyo LGG conferred survival advantage over control untreated mice. 2 mice in the 
Immucyst group died before the tissues could be collected for analysis, and had to be 
excluded from subsequent analysis as a result. Therefore the sample size for Immucyst 
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was corrected to n = 13. Tumour presence was confirmed visually and by urine and 
bladder protein free-PSA ELISA analysis. Of the 4 mice that died in the Immucyst group, 
all but one had bladder tumour. The cause of death could not be determined for that 
mouse. Table 3.17 summarises the odds ratio of mice bearing tumour with respect to their 
treatment.  
 






# OR 95% CI p-value 
Control 
(PBS) 
10 3 8 1.0 - - 
Immucyst 13 4 3 0.075 0.010 - 0.563 0.012 
Lyo LGG 9 2 1 0.031 0.002 - 0.418 0.009 




Figure 3.15 Kaplan Meier analysis of BGC and lyo LGG therapy on the survival of 
tumour-bearing mice. Mice received 6 weekly instillations of PBS, Lyo LGG or 
Immucyst. Surviving mice were terminated at day 40 – 1 day after the 6th instillation. 
Control (n = 10), lyo LGG (n = 9) and Immucyst (n = 13). 
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3.4.2.3 Lyo LGG and Immucyst and tumour metastasis 
Metastasis was confirmed with real-time PCR using PSA-specific primers; tissues that 
presented with gross pathology were tested. It was found that none of the treatments 
specifically predisposed the mice to metastasis. It should be noted however, that the 
possibility of metastasis as a result of retrograde instillations during tumour implantation 
procedures could not be ruled out here. Table 3.18 summarises the number of mice with 
metastasis and the sites to which the tumour spread, and the likelihood of tumour-spread 
in each treatment group.  
 
 
Table 3.18. Number of mice that presented with metastasis at end-point. 













Lung (1) 25% - 
Immucyst  




Kidney (1) 33% 0.465 
Lyo LGG 




NA 0% 0.999 
‘NA’ indicates not applicable. All comparisons are made with respect to control as the 
basis of reference.  
 
1 mouse in the lyo LGG group had pyelonephritis and presented with kidney-lung 
adhesion. The mouse was terminated prematurely and the tissues were harvested for 
further analysis. It was subsequently found that the mouse was already cured of bladder 




3.4.3 Lyo LGG and BCG instillations did not alter urine TNFα and IL10 levels 
It has been reported that BCG instillations lead to increased urinary TNFα [32], 
which in turn mediates anti-tumour activities, while IL10 presence suppresses it. To 
determine if lyo LGG instillations could do the same, urine was collected 1 day before 
instillation, i.e. 1 week after the 4th, 5th and 6th instillations. Urine from controls was also 
collected basal cytokine analysis. Urine could not be collected from the Immucyst BCG 
group at these time-points due to IACUC restrictions (discussed in Section 3.4.2.1).   
TNFα and IL10 levels in the urine that were collected 1 week after the last 
instillation were comparable between lyo LGG mice and controls (Figure 3.16). The 
presence of a bladder tumour also did not influence the cytokine levels.  
As the lack of cytokine response may be attributable to the lack of antigenic 
stimulation, since it was found earlier that LGG did not persist in the bladder for longer 
than 12 hr, urine was also collected immediately after the last (6th) instillation for control 
and lyo LGG group; Urine from the Immucyst group was collected before the mice were 
sacrificed. There was no significant elevation in urinary TNFα or IL10 levels in all three 
groups. This observation was also confirmed with 100 µg bladder proteins using TNFα 












Figure 3.16. Urinary TNFα and IL10 1 week after lyo LGG instillations. Urine was 
collected 1 week after the 1st (A), 4th (B) and 5th (C) instillations. Urine TNFα and IL10 
were comparable with controls (PBS instilled). Each data represents a mouse and data 






A B C 
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3.4.4 Lyo LGG increased TNFα mRNA expression in local lymph nodes 
 
The establishment of an immune response against cancer may depend on the 
capacity of immune cells in regional lymph nodes to induce a specific response leading to 
tumour rejection. As such, real-time PCR analysis was performed on lymph nodes to 
determine the expressions of TNFα, IL10 and TGFβ in response to lyo LGG and 
Immucyst therapies. 
It was found that bacteria (Immucyst and lyo LGG) instillations generally 
upregulated IL10, TGFβ and TNFα expressions in the local lymph nodes, but only lyo 
LGG could significantly upregulate TNFα expression (p <0.05) (Figure 3.17).  
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Figure 3.17. Microbe instillations elevated TNFα, TGFβ and IL10 transcript 
expression in local lymph nodes. With real-time PCR , it was found that 6 weekly lyo 
LGG and Immucyst instillations slightly elevated the Th2 cytokine IL10 (A) and tumour 
suppressor TGFβ (B) mRNA in the lymph nodes, but only lyo LGG instillations 
significantly upregulated TNFα expression (C). Data is expressed as mean ± SD; 







Lyo LGG was as efficacious as standard Immucyst BCG as a cancer 
immunotherapeutic. While it appeared that lyo LGG did not mediate anti-tumour effects 
via the production of TNFα in the bladder, lyo LGG did however, significantly 
upregulate TNFα expression in the local lymph nodes, the consequence of which may be 




















3.5 Analysis of direct cytotoxic effects of LGG  
It has been reported that LGG has growth inhibitory effects on human bladder cancer cell 
lines [95]. In order to further characterise the anti-tumour and cytotoxic mechanisms of 
LGG, in vitro experiments were done.  
 
3.5.1 Live LGG but not heat-killed LGG induces cytotoxicity 
It has been reported that the viability of bacteria can affect its cytotoxic efficacy [145 
146] as such heat-killed LGG’s ability to induce cell death was compared with live LGG. 
It was found that heat-killed bacteria did not mediate cell killing even after 72 hr of 
treatment; only live LGG in Penicillin G only media (no inhibition of bacteria protein 



























Figure 3.18. Total number of MGH cells remaining in wells after 24, 48 and 72 hr of 
LGG treatment. Heat-killed LGG did not elicit cytotoxic effects; treated cells 
proliferated as well as controls. Only cells treated with live LGG in the absence of 
streptomycin had significantly (*p < 0.05) fewer cells after 72 hr. The experiment was 
done thrice with duplicates; data expressed as mean ± SD.  
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3.5.2 Live LGG inhibits murine and human bladder cancer cell proliferation  
 
To determine if LGG treatment imparted an anti proliferative effect against 
bladder cells, cancer cells were labeled with Calcein AM prior to treatment. When cells 
proliferate, the amount of calcein decreases and the change in fluorescence intensity can 
be measured by flow cytometry. As shown in Figure 3.19A, live LGG treatment inhibited 
the growth of MB49 and MGH cells after 48 hr. However, cell growth inhibition was 
minimally affected when streptomycin (a prokaryotic protein synthesis inhibitor) was 
present, indicating the involvement of a de novo anti-tumour bacteria protein (Figure 
3.19B). 
         
 
 
Figure 3.19. Monitoring cell proliferation with Calcein AM. Retention of calcein AM 
in live LGG-treated MGH compared to controls in PG media (A) and PGS media (B). 
Red line represents cells freshly stained with calcein AM (time 0 hr). Green and blue 
lines represent 24 and 48 hr untreated controls respectively. In untreated cells, 
fluorescence intensity were reduced every 24 hr, indicative of cell proliferation. Shaded 
block (  ) represents LGG-treated sample (PG media); after 48 hr, cell proliferation in 
treated samples was halted between time 0 and 24 hr (A). The anti-proliferative effect 






3.5.3 LGG induces sub-G1 population in the absence of direct contact with cancer 
cells  
 
Flow cytometric DNA analysis with propidium iodide (PI) was used to study the 
effects of LGG on cell cycle progression. While the presence of sub-G1 cell population is 
indicative of apoptosis or necrosis, it does not discriminate between the 2 types of cell 
death.  
It was found that cells treated with LGG in PG media had the largest population 
of sub-G1 cells after 72 hr, indicating apoptosis induction by LGG. The presence of a cell 
culture insert which segregated bacteria from mammalian cells did not impede the cell 
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Figure 3.20. LGG induced a significant sub-G1 cell population. MB49-PSA cells 
treated with LGG in PG media (PG LGG) had the most number of cells arrested in the 
sub-G1 phase (‘*’denotes p < 0.05) after 72 hr. LGG continued to induce a significant 
anti-tumour effect despite the absence of bacteria-mammalian cell contact (PG LGG + I). 
Experiments were performed thrice each time in duplicates.  
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3.5.4 Lyo LGG is as efficacious as live LGG in inducing a large sub-G1 population  
 
Since lyo LGG was more efficacious than live LGG in inducing cytokine 
production, lyo LGG’s ability to induce cell cycle arrest in MGH cells was compared to 
the latter. It was found that lyo LGG could induce cell cycle arrest to the same extent. 
The sub-G1 cell population in treated wells was almost double that of control (p < 0.05) 
despite the inclusion of cell culture inserts, again indicating a soluble cytotoxic 
metabolite; the sub-G1 cell population was greater at 72 hr than at 48 hr (Table 3.19). 
 
Table 3.19. Percentage MGH cell population in sub-G1 phase after co-culture with 
live or lyo LGG.  
(‘*’denotes p < 0.05 with respect to control) 
 
3.5.5 LGG increases NAG-1 mRNA expression in MGH cells  
NAG-1 has been reported to possess anti-tumourigenic and pro-apoptotic 
activities in vitro. As it was observed that both live and lyo LGG arrested both human 
and murine bladder cancer cells at the sub-G1 phase, which was indicative of cells 
undergoing apoptosis, NAG-1 transcripts levels in MGH cells were analysed to determine 
if they were upregulated after LGG treatment.  
Prior to the assay, a dissociation curve analysis was performed on the 18srRNA 







3.453 ± 0.815% 6.85 ± 1.36% 
Live LGG 
 
9.704 ± 2.576%* 12.41 ± 1.946%* 
Lyo LGG 
 
10.08 ± 1.695%* 14.63 ± 2.66%* 
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18srRNA and NAG-1 (Figures 3.21A and 3.21B respectively) showed no non-specific 
amplification indicating optimal primer specificity and reagent concentrations. 
Contaminating DNA or primer dimers would show up as an additional peak separate 






Figure 3.21. Derivative dissociation curves for 18srRNA endogeneous control (A) 













Following the primer optimisation step, the real-time PCR was performed and it 
was found that LGG induced and increased NAG-1 mRNA and protein levels in a time-
dependent manner. The number of NAG-1 mRNA transcripts was significantly elevated 
in the live and lyo groups from 48 hr peaking at 72 hr after treatment (Figure 3.22). 
Although NAG-1 transcripts could also be detected at 24 hr, the level of expression was 
comparable among the groups. 
 
Figure 3.22. NAG-1 expression in MGH cells following LGG treatment. It was found 
with real-time PCR that MGH cells significantly increased NAG-1 mRNA expression 
from 48 hr through to 72 hr after treatment with live LGG and lyo LGG. The level of 
expression was higher at 72 hr than at 48 hr. Data is presented as mean ± SD; ‘*’ denotes 
p < 0.05 compared to untreated controls.  
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3.5.6 LGG did not induce caspase-3 activity 
On seeing that LGG is able to inhibit cell proliferation, induce cell death with 
concurrent NAG-1 upregulation, the next step was to determine the form of cell death 
which LGG induced. Caspase-3 activity is symbolic of apoptosis and as such 100 µg total 
protein from 72 hr control and lyo LGG treated MGH cells was analysed for caspase-3 
activity. However, no caspase-3 activity was detected and as such it could not be 
concluded that LGG mediated cell death via apoptosis.  
 
3.5.7 Live and lyo LGG induces cell death in MGH cells  
 
Electron microscopy provides the most information about tumour cell 
morphology and has served as a ‘‘gold standard’’ for distinguishing apoptosis from 
autophagy and necrosis. Since live and lyo LGG-treated cells (MGH and MB49-PSA) 
invariably appeared stressed and dying, and they were often seen rounded and detached 
from the culture dishes after 72 hr closer examination with electron microscopy detailing 
the ultrastructures of treated MGH cells was carried out. It was found that many of the 
cells in the LGG-treated samples presented with multiple unstained areas giving a moth-
eaten morphology. Treated cells also had distorted nuclei, degrading plasma membranes, 
loss of organelles and many more lipid droplets than controls. All of which are 
morphologies characteristic of necrotic cells (Figures 3.23 and 3.24). It should also be 
noted at this point that the double membranous vesicles typical of autophagosomes were 












Figure 3.23. Representative electron micrographs of MGH cells co-cultured with 
LGG for 72 hr. Untreated MGH cells (A & B). Cells treated with live or lyo LGG had 
more lipid droplets (arrows) (C & D). Treated cells also presented with distorted nuclei 
and disintegrating plasma membranes (dashed arrows), all of which are morphological 

















Figure 3.24. Representative high magnification images of MGH cells treated with 
live or lyo LGG.  Panels A and B are representative images of MGH cells laden with 
lipid droplets (arrow pointing) after treatment with live or lyo LGG. Treated cells had 
distorted nucleus and a moth-eaten appearance (C & D). Lipid droplets at higher 












Living but not heat-killed LGG can induce cytotoxicity in vitro. Both live and lyo 
LGG induced a significant accumulation of cells in the sub-G1 phase in a time-dependent 
manner with cells showing necrotic characteristics and no observable caspase-3 activity. 
























































Although BCG therapy is effective in delaying disease recurrence, side-effects are 
common and can be debilitating and some patients do not respond to therapy [147, 148]. 
Thus, there is a need for other effective remedies that has minimal side-effects to replace 
BCG as an immunotherapeutic. 
Lactobacillus species are generally-regarded-as-safe organisms that are used as 
probiotics. The use of probiotics, in particular, the genus Lactobacillus in urology is not 
new. They have been used in treating recurrent urogenital infections [56, 149], bladder 
cancer recurrence and renal stone formation [150]. Clinical trials with oral Lactobacillus 
preparations have proven well-tolerated and largely free of adverse effects in bladder 
cancer patients. In Japan, trials involving 30 hospitals and medical centres with a total of 
173 patients have shown that orally administered viable Lactobacillus casei strain Shirota 
or LcS treatment ensured a 50% recurrence-free period of superficial bladder cancer [91]. 
Aside from this, experiments with animal models have also demonstrated the 
tumouricidal effects of LcS. Takahashi et al used C3H/He mice orthotopically implanted 
with MBT-2 murine bladder cancer cells and showed that intravesical LcS was as 
effective as BCG [94]. However, this model was not known to respond well to BCG. In a 
separate report, oral LGG, a lactobacillus originally isolated from the human gut, was 
shown to be effective against the subcutaneous murine bladder tumour [93].  
These studies and others provide evidence of Lactobacillus species’ protective 
effects in the early stages of bladder cancer and simultaneously proved they are effective 
in treating the cancer. What was lacking however, was the exploration of Lactobacillus 
species as intravesical agents as adjuvants to surgery in the treatment of superficial 
bladder cancer. The following segments summarise the use of LGG as an intravesical 
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immunotherapeutic agent as well as illustrate the likely mechanisms (direct and indirect) 
via which LGG mediates its anti-tumour based on the data gathered from this series of 
investigations.  
 
4.1 LGG as a non-pathogenic intravesical immunotherapeutic 
Being a commensal, LGG is likely to be better tolerated than BCG and to 
demonstrate this, healthy C57BL/6 mice were administered 4 - 6 weekly instillations of 
live viable LGG and monitored for LGG persistence and local and systemic immune 
response changes. This was done after verifying LGG’s potential to stimulate TNFα and 
IL12p40 (Th1) and IL10 (Th2) production in splenocytes. Since this was a study on the 
efficacy of LGG as an immunostimulant and immunotherapeutic agent in vivo, live BCG 
was included as a comparison. Gene expressions were monitored after 4 - 6 weekly 
instillations of the microbes because a minimum of 4 BCG instillations is required before 
discernible cytokine responses can be observed in animals and the urine of patients [151, 
152]. Experimental studies by Hudson et al. [153] in 1989 showed that the optimum 
duration of exposure for maximal binding of BCG to fibronectin and successful immune 
response initiation in the bladder was 2 hr, as such catheters were kept in place for 2 hr 
after instillation to ensure maximum bacteria retention and at the same time minimise 
voluntary voiding.  
At the end of the duration of the experiment, all LGG and BCG mice remained 
healthy. However, juxtaposed to live BCG, the immune response induced by live LGG 
seemed feeble – live BCG upregulated up to 15 genes in the bladder and live LGG 
managed only one (IL1r2) while suppressing 2 others (Cxcl13 and Mif). Live BCG 
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significantly upregulated the expressions of Cxcl9, Cxcl10, Ccl7, IL1ß, Ccl2, MIP2 
(Cxcl2), Xcl1 and Fcεr1 and increased TNF-α, Ccl5, Ccl6 and iNOS as early as the 4th 
instillation. Of these chemokines, Ccl5, Ccl2, and Cxcl10 have already been identified in 
patient’s urine after BCG therapy [38, 154, 155]. Ccl2, Ccl6 and Cxcl2 recruit 
monocytes/ macrophages [156, 157] and polymorphonuclear cells (PMNs) [158, 159]; 
Ccl7 recruits eosinophils [160] while Ccl5 recruits T cells as well. Fcεr 1 is present is 
great abundance in mast cells and basophils [161], as such increased Fcεr 1 expression 
probably indicated infiltration of mast cells, basophils and eosinophils. Cxcl9, which 
drives CD4+ T lymphocyte proliferation [162], and Cxcl10, an NK and T cell attractant 
may have been induced by TNF-α and IL1β. Activated NK cells in turn secrete Xcl1 
which recruits T cells and neutrophils [160, 163]. Fcγr1 is necessary for antibody 
mediated uptake of bacteria by phagosomes [164] and so its induction as well as that of 
iNOS probably correlates with phagocytosis of BCG. IgE/IgA binding to FcεR1 will 
induce the production of further inflammatory mediators [165]. As expected these gene 
expression changes caused an increase in the number of cells in the lymph nodes by 4 
weeks but significant NK cell accumulation was only observed after 6 weeks of BCG 
instillation. The observed gene expression changes were produced by immune cells 
recruited into the bladder by the presence of BCG and subsequent exposure of these cells 
to weekly instillations of BCG will result in more cytokines or chemokines being 
secreted which will again attract and activate more immune cells, as shown in Fig. 4.1 
This inflammatory response of immune cells to BCG serves to clear and destroy the BCG 
in the bladder and inadvertently this destroys any tumour cells in the vicinity [166 – 168].  
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The fact that live LGG was not as robust as live BCG did not come as surprise 
since it was found using LGG-GFP that the number of viable LGG quickly decreased, 
with less than 1x103 - 6.67x104 cfu still retained in the bladder just 6 hr after instillation. 
This observation was similar to BCG’s, in that BCG is poorly retained in intact 
urothelium [169] and like BCG, repeated LGG instillations (6 in total) resulted in 
increased LGG localisation in the bladder. In fact LGG accumulation was found to be 
inversely proportional to the gene expression changes observed. These results appeared to 
be consistent with studies that report that Lactobacillus species decrease the production 
of pro-inflammatory cytokines [170] and have thus been used to prevent and/or suppress 
immune responses in patients with eczema, inflammatory Crohn’s disease [171] and 
bacterial gastroenteritis.   
In addition to the genes detected by the array, it was found with semi-quantitative 
PCR that LGG instillations also induced transient upregulation of Cxcl10, IL16, Fcεr1 
mRNA, and IL1r2 at 4 weeks. IL16 is a chemoattractant for NK and T cells. It is possible 
that the increase in Cxcl10 and IL16 at 4 weeks was sufficient to attract NK cells as LGG 
instillation did cause increased NK accumulation in the bladder and draining lymph 
nodes from the 5th - 6th weeks. IL1r2 is an inert receptor for IL1 and may mitigate the 
inflammatory response induced by the slight increase in IL1β at 4 weeks [172] IL1β 
decreased by 6 weeks and so did the levels of IL1r2. This pattern of expression was also 
observed with BCG. After 6 weekly instillations TNFα expression in the bladder was 
suppressed by LGG in contrast to the increase in TNFα production observed on exposure 
of splenocytes to LGG. Neither TGFβ nor Foxp3 were induced by LGG thus the lack of 
gene expression is not be due to recruitment of T regulatory cells.  
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Since the array used in this analysis was a pathway-specific array and so did not 
have full genome coverage, it was thus very likely that LGG induced genes not present 
on the array. It could be possible that LGG caused increased translation rather than 
transcription of chemokine or cytokine genes.  
Although the recruitment of NK cells into the bladder after LGG instillation was 
not consistent with immunosuppression, Lactobacillus consumption has been reported to 
activate macrophages and neutrophils and stimulate secretory IgA without the release of 
inflammatory cytokines [173, 174]. This activation may be the result of secreted proteins 
from lactobacilli that are themselves immune cell chemoattractants such as 
“Gasserokine” produced by L. gasseri [175]. The increased NK cell recruitment did 
coincide with increased LGG in the bladder at 6 weeks which does lend some credence to 






Figure 4.1. A schematic diagram of the immune changes following microbe instillations. After 4 instillations, live BCG 
instillations resulted in the upregulation of IFNg in the bladder. As a result of which, endothelial cells and macrophages/ monocytes 
are activated to produce Cxcl9 and 10. Subsequent BCG instillations resulted in more chemokine and cytokine  genes being 
upregulated culminating in a strong immune response to aid in BCG clearance. On the hand, live LGG induced fewer genes to be 
upregulated. Live LGG may have also induced the upregulation of other gene transcripts which may have led to NK recruitment, but 
which were not inuclded in this series of analysis. Genes induced are shown by arrows pointing up and those down regulated by  
arrows pointing down.
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4.2 Lyophilised LGG - a better immunostimulant than whole live LGG 
The poor immune response induced by live LGG may be because whole live 
bacterium was less immunogenic than a bacteria preparation consisting of bacteria debris. 
Several reports have cited the immunomodulatory and anti-tumour effects of 
lactobacillus-derived cytoplasmic fractions [88] and peptidoglycan [176] suggesting that 
whole bacteria are not as immunogenic as their fractions. This proved to be true when 
lyophilisation was found to improve LGG’s immunogenicity. Fresh overnight LGG 
cultures were lyophilised and stored. The lyophilised LGG were reconstituted to the 
appropriate dilutions just before instillation. Lyophilised LGG (lyo LGG) was 
consequently found to upregulate more genes (7 in total) than observed with live LGG. 
Separately, a twice-weekly lyo LGG instillation schedule saw a total of 13 genes being 
upregulated. This was almost comparable to the immune response induced by live BCG 
earlier.  
Lyophilisation is the most common drying method for improving the stability of 
pharmaceuticals including those for parenteral administration [137, 138].  Lyophilising 
bacteria also reduces the need to constantly maintain a ‘live’ bacteria culture, thereby 
reducing the chances of culture contamination and strain variation as a result of 
prolonged culture. At the same time, lyophilised materials are more convenient for 
transport. They also generally contain a lower dose of viable bacteria, hence reducing the 
risk of systemic infections. This is of particular importance since this preparation will be 
given intravesically to bladder cancer patients. While lyophilisation ensures stability, it 
can generate various stresses during freezing and drying steps which can cause bacteria 
cell lysis resulting in the release of LGG peptidoglycan fragments and cytoplasmic 
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proteins all of which may contribute to the observed increased immunogenicity of lyo 
LGG.  In addition to these considerations, the increased instillation frequency (2 
instillations per week) likely led to an accumulation in the amount of LGG debris, hence 
the heightened mRNA expressions detected by the pathway specific microarray. In spite 
of the differential gene expressions between the 2 instillation schedules, the specific 
immune cell populations in the bladder were not exceptionally different.   
DCs are potent antigen presenting cells and are distributed in most tissues, in 
particular, at sites that interface with external environment, including the bladder lumen 
albeit at low levels [177]. The central dogma of DC migration is as such - inflammatory 
stimuli promote recruitment of immature DCs into tissues where they then encounter and 
uptake antigens. This is followed by a complex series of activation and maturation 
process leading to the eventual migration of activated (CD11c+CD83+) and mature 
(CD11c+CD86+)  DCs from peripheral tissues into draining lymph nodes, where they 
interact and present processed antigens to resting T cells [178]. In the series of flow 
cytometric analysis on DC cell populations following once or twice weekly lyo LGG 
instillations, there were significantly more CD11c+CD83+ and CD11c+CD86+ DCs in lyo 
LGG bladders than in PBS controls. It is likely that lyo LGG are potent inducers of 
resident bladder DCs resulting in a rapid upregulation of CD83 and CD86 cell surface 
markers, thereby accounting for their high numbers in lyo LGG-treated bladders. This is 
congruent with observations made by Drakes et al where the co-culturing of viable L. 
casei or lyophilized probiotic mixtures with DCs lead to an increased percentage of 
CD11c+ cells expressing CD80, CD86, CD40 DC [179] indicating that Lactobacillus 
species have the propensity to activate resident immature DCs. It has been reported that 
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mature DCs but not immature DCs are more efficient at migrating to lymph nodes and as 
such are more effective at mounting a proper immune response than immature DCs [180], 
hence lyo LGG’s ability to rapidly activate immature DCs may eventually serve as 
LGG’s anti-tumour mechanism since DCs have the potential to break tumour tolerance 
and induce tumour-specific immune responses leading to tumour rejection [139]. 
While unconventional, the concurrent fall in neighbouring lymph node 
CD11c+CD83+ and CD11c+CD86+ DCs seem to suggest the exodus of these cells into the 
lyo LGG bladders. Certainly more work needs to be done to verify this.  
Macrophages like DCs are the first barrier against infections. They are located in 
tissues throughout the body where they detect foreign antigens. Various strains of 
probiotic lactobacilli, e.g. LGG, L. reuteri, and LcS, are well documented in their ability 
to augment macrophage phagocytic activities and cytokine production when administered 
perorally or intraperitoneally [181]. However, fewer macrophages were observed in the 
bladders and LN of mice that received 2 intravesical doses of lyo LGG a week.  There 
were also significantly fewer NK cells in lymph nodes of these mice but no increase in 
the bladder. This may reflect systemic activation in these mice rather than just local 
responses. The NK accumulation observed with live LGG was notably absent, indicating 
live and lyo LGG preferentially recruited and/or activated different types of immune 
cells.  
Lyo LGG was also found to differentially recruit B cells or stimulated their 
proliferation depending on whether it was given once or twice a week. The number of 
B220+ cells was significantly increased in the lymph nodes of mice that received 1 
instillation a week, but only slightly elevated in mice that had 2 instillations per week. 
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B220 is expressed on B-lymphocytes at all stages from pro-B through to mature and 
activated B cellsf [182, 183]. DCs carrying LGG-derived antigens to the lymph nodes, 
may have presented their antigens to B cells, which in turn activated them. Once 
activated, B cells multiply and produce neutralising antibodies to clear the microbes.  
While lyophilisation did well to augment LGG’s immunogenicity, the same was 
not observed for Immucyst (lyophilised BCG) the latter contains viable BCG albeit at 
small quantities along with BCG fragments, which are thought to be more immunogenic 
than whole live BCG [184]. It was indeed unexpected to find the latter induce a far more 
humble response with respect to live BGC and lyo LGG. In any case, BCG is not known 
to persist well in healthy bladders due to the scarcity of fibronectin receptors in intact 
urothelium [23, 169]. Other confounding factors like urine, time of contact between cells 
and BCG and the glycosaminoglycan layer in the bladder may also have affected the 












4.3 cRNA array versus semi-quantitative polymerase chain reaction 
The pathway-specific array was used with the primary goal focusing on the local 
inflammatory responses following live BCG or live LGG instillations into the bladder. In 
summary the pathway specific microarray along with flow cytometric analysis 
demonstrated that all 4 bacteria preparations – live LGG, lyophilised LGG (lyo LGG), 
live BCG and lyophilised BCG (Immucyst) exhibited varying capacities to invoke an 
immune response in a non-diseased bladder. The differential gene expression was 
corroborated with semi-quantitative PCR (except for Cxcl13 and Mif) with RNA 
extracted from other mice. However, only 50% of the 15 genes identified on the array 
were found to be upregulated. Another 21% of genes had the same trend of gene 
expression changes with time (between 5 and 6 weeks). The poor reproducibility of the 
array may be because the cRNA used to probe the array was linearly amplified from 
cDNA rather than exponentially amplified as in PCR. This might have led to most of the 
genes being below the detection limit of the array as was seen when a further 20 genes 
not detected by the array were selected for RT-PCR analysis. Of these 7/20 had an 
approximate 2-fold increase in expression; the remaining 13/20 either showed no change 
or were not detected.  
Also, at the moment, only 1 mouse bladder from each group was used for the 
array. Array data reproducibility and sensitivity will likely improve with at least 2 
independent array experiments followed by more stringent statistical analyses e.g. 
ensuring differentially expressed genes could pass 2 sets of statistical criteria before they 
are considered significant and shortlisted for downstream confirmation.  
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The cytokine genes were detectable when 5µg of total RNA were used for cDNA 
synthesis, while 1µg total RNA sufficed for the chemokines (except Cxcl14 and Cxcl13), 
indicating that chemokines were more abundant than cytokines following BCG 
instillations. In spite of this, the fact remains that lyophilised LGG can be recognised as 
an antigen and it activates the cellular immunity system. 
 
4.4 Treating bladder cancer with Lactobacillus rhamnosus strain GG  
The next and penultimate aim was to test its feasibility and clinical application as 
an adjuvant to surgery in treating bladder cancer. Using the PLL technique with MB49-
PSA cells, which ensured high tumour implantation and monitoring of disease 
progression, a ‘one-instillation-per-week’ schedule was adopted for therapy, as it was 
envisioned to be more practical without requiring the patient to return to the clinic 
regularly unlike a twice-weekly instillation schedule. 
Therapy began four days post-tumour implantation since the tumour load at this 
time emulated a bladder that had undergone recent transurethral resection. Lyo LGG was 
found to be as competent as lyo BCG (Immucyst) in eradicating the tumour yet eliciting 
only an adequate immune response. In contrast, Immucyst resulted in severe 
inflammation and an eventual failure for successful instillation. Although instillation was 
usually restored after a week’s rest, the resultant inflammation meant that some BCG 
mice did not receive all 6 instillations. The delay or interruptions of the instillations did 
not significantly reduce the efficacy of treatment. The BCG-phenomenon was however 
not unique to this model given the high immunogenicity of BCG.  
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Like LcS, both lyophilised and live LGG were found to be effective in eradicating 
the bladder tumour. It thus appears being tumouricial toward bladder cancer cells is a 
common trait of the L. casei group. While oral therapies with various LcS preparations 
have proved effective in treating bladder cancer and delaying recurrence and disease 
progression [87, 91, 92, 185] oral LGG was not found to further augment the treatment 
efficacy of lyo LGG instillations. However, given that oral therapy is less invasive and 
probably more acceptable to patients the next prerogative should be to explore LGG as an 
oral immunotherapeutic in bladder cancer treatment. It may also be beneficial to 
investigate if oral lyo LGG will be synergistic or antagonistic to BCG’s efficacy.  
 
4.5 LGG’s indirect killing mechanisms 
4.5.1 Role of proteins  
In trying to elucidate and identify the molecular mechanisms of LGG’s anti-
tumour action, a cytokine protein array was used to identify and profile the changes in 
cytokine or chemokine levels after LGG therapy. Bladders were resected from mice one 
day after the last (6th) lyo LGG instillation; 1mg of bladder proteins was used for the 
array. Control PBS-instilled live LGG instilled and mice that received oral live LGG in 
addition to lyo LGG instillations (O+I) were also analysed. The array was used as a rapid 
and preliminary analysis to shortlist the proteins that may be LGG’s effector molecules.  
After verifying with commercial ELISA, it was established for the first time that 
MB49-PSA cells constitutively expressed E-selectin, OPN, Pro-MMP9, VEGF-D, 
VEGF-R2, Lymphotactin and TNFα in vitro. E-selectin and OPN were highly expressed 
by MB49-PSA in vitro. Healthy bladders were also found to express the panel of proteins 
 143
basally, although tumour-bearing bladders expressed OPN and Pro-MMP9 at higher 
quantities than healthy bladders indicating that these proteins are differentially expressed 
in different pathologies. Like human cancer, MB49-PSA also expressed Pro-MMP9 and 
OPN thereby accounting for their detection in tumour-bearing mice. The expression and 
overexpression of these proteins are related with active transitional cell carcinoma, 
higher-grade tumours and increased pathological stage [186 – 188]. Enhanced expression 
of Pro-MMP9 is associated with human tumour invasion and/or metastasis and 
expression has been strongly correlated with presence of bladder cancer [186], yet, lyo 
LGG but not live LGG instillations were found to diminish the amounts of these proteins 
circulating in the bladder, to levels comparable to that of healthy bladders. These data 
implied that aside from being tumouricidal, lyo LGG could prevent metastasis and 
disease progression.  
Another protein that was found to be differentially expressed as a result of LGG 
instillations was Lymphotactin, a chemoattractant for lymphocytes (but not for 
neutrophils) [143]. When all 3 LGG treatment groups were analysed collectively, 
Lymphotactin was found to be significantly higher in bladders that received LGG than 
control PBS-instilled ones. It could thus be inferred that repeated LGG instillations can 
lead to the infiltration of lymphocytes possibly to aid in tumour eradication.  
At the same time it was observed that oral feedings of live LGG in addition to lyo 
LGG instillations were found to significantly elevate VEGF-D in the bladder. VEGF-D is 
a potent angiogenic factor in vivo whose primary role is to stimulate endothelial cell 
proliferation and migration. While VEGF-D expression and the physiological 
lymphangiogensis that follows has also been associated with tumour angiogenesis [189] 
 144
it was more likely that oral feedings of LGG increased lymph vessel density leading to 
eventual immune cell recruitment rather than having facilitated tumour growth.  
It has also been widely suggested that TNFα is one of the primary anti-tumour 
effectors of BCG and LcS [32, 94, 190] but it did not seem to be the case here. Instead, 
TNFα was found in all bladder samples regardless of pathology and therapy. A 
comparison of urine TNFα levels one week after instillation, and immediately thereafter 
also brought showed no significant alterations in TNFα protein levels. This was 
somewhat different from the in vitro observations made earlier where LGG was found to 
significantly induce TNFα, IL12p40 and IL10 in splenocytes. This is because the 
splenocyte culture is composed of a complex and eclectic mix of immune cells and LGG 
instillations may not have recruited immune cells in the same ratio and proportion as in 
the splenocytes, and hence was not able to effect the same response. As such it could not 
be concluded that LGG did not mediate tumour killing via inducing TNFα production in 
the bladder.  
Despite not having observed a direct involvement of TNFα in the bladder, lyo 
LGG instillations was found to significantly upregulate TNFα mRNA transcripts in the 
local lymph nodes of tumour-bearing mice. Like the splenocyte culture, the lymph nodes 
consist of numerous lymphocytes, macrophages, and dendritic cells that contain and 
secrete a variety of cytokines. The first sign of “LGG infection” can tilt the immune 
equilibrium towards a pro-inflammatory environment. The constant influx of bladder 
tumour-associated antigens coupled with an increased number of foreign LGG-associated 
epitopes may have promoted a Th1 environment in the lymph nodes thus explaining the 
up-regulation of TNFα in the lymph nodes of lyo LGG-treated mice. In contrast, 
 145
Immucyst only weakly elevated TNFα mRNA copy numbers. It thus appeared that LGG 
engaged and mobilised local lymph nodes to induce a specific response leading to tumour 
eradication. This notion is bolstered by the observed changes in neutrophilic and Ly6G+ 
granulocytes populations in the bladder and lymph nodes following lyo LGG instillations.  
 
4.5.2 Role of immune cells  
Figure 4.2 is an illustrated summary of the possible immune cell changes after 
LGG instillations. Briefly, with the use of immunohistochemical techniques, it was found 
that lyo LGG instillation could also induce massive neutrophilic transmigration into the 
tumour from as early as 24 hr after the 2nd instillation. There has been increasing 
evidence that neutrophil granulocytes are required for effective BCG immunotherapy [36, 
191]. They are recruited from as early as 24 hr after the 1st instillation [36, 191] and may 
be there from the beginning to the end of treatment [191]. Neutrophils are believed to 
mediate leukocyte chemotaxis to the bladder as an early inflammatory response [36, 192]. 
Their presence is described as indispensable as depletion experiments completely 
abrogated BCG anti-tumour response as a result of impairment in CD4+ T-cell 
recruitment [192] due to the lack of chemoattractive cytokines [192, 193]. It has also 
been suggested that polymorphonuclear neutrophils can mediate direct anti-tumour 
activity via the release of granules and enzymes resulting in damage and shedding of 
urothelial cells [191]. It should be noted that mice in the LGG-instilled groups are 
typically devoid of bladder tumours between the 2nd and 3rd instillations indicating the 
role of neutrophils in LGG’s indirection anti-tumour mechanisms. In contrast, neutrophils 
were either absent or only present sparsely in controls. The sharp rise in bladder 
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neutrophil numbers along with the observed reduction of Ly6G+ cells (granulocytes) in 
the local lymph nodes after 6 weeks of lyo LGG instillations, along with the increased 
amounts of bladder Lymphotactin, further galvanise the notion of lyo LGG mobilising 
neutrophils as warriors against the bladder tumour cells.  
At the same time that neutrophils were detected in the tumours of both controls 
and lyo LGG-mice, there was also noticeable macrophage infiltration along the tumour 
periphery. It is known that macrophages can be tumouricidal and are often attracted to 
tumours because of the growth factors and chemokines, which are often, produced by the 
tumour cells themselves [194, 195] and can meditate tumouricidal effects, and it was 
found that lyo LGG led to an increased macrophage presence in the tumour. The 
infiltration of neutrophils and macrophages were similarly observed by Takahashi et al 
[84] when they instilled bladder tumour-bearing C3H/He mice with LcS preparation.  
It was also found earlier that weekly instillations of lyo LGG reduced mature and 
activated DC numbers in the local lymph nodes, but increased the numbers of these cells 
in the healthy bladder, so it may be plausible that lyo LGG instillations also actively 
recruited activated and mature DCs and T-cells into the tumour. Both live and lyo LGG 
instillations had significantly elevated the Lymphotactin and IL16 levels in the tumour-
bearing and cured mice bladders, and in healthy bladder respectively, both of which are 
chemoattractants for T-cells.  
It could hence be postulated that LGG mediated anti-tumour immunity via the 
augmentation and activation of local immune cells or local lymph nodes. Despite all the 
immune changes taking place in the bladder and neighbouring lymph nodes, there were 
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minimal changes in the splenic population. This observation was the same as BCG – both 













Figure 4.2.Proposed LGG anti-tumour mechanisms. Upon the 2nd instillation, LGG 
recruits large numbers of polymorphonuclear cells (PMNs) from the neighbouring lymph 
nodes (LN) to the bladder. PMNs release a myriad of cytokines that are chemoattractants 
for lymphocytes. At the same time granules and enzymes from PMNs elicit anti-tumour 
responses as indicated by ‘X’. Tumour is indicated by ‘T’. Lyo LGG also attracts 
macrophages (Mφ) to the bladder simultaneously. These immune cells may be directly 
tumouricidal or act via the action of CD4+ T-cells which they activate. These activities 
constitute the early acute inflammation and are believed to be the main mechanism via 
which lyo LGG mediates it anti-tumour effects. Subsequent lyo LGG instillations 
increased Xcl1 (Lymphotactin) levels in the bladder which may in turn lead to increased 
T and B lymphocyte presence in the bladder augmenting the tumouricidal response. 
Repeated lyo LGG instillations (4th – 6th instillation) also likely led to a reduction in the 
Pro-MMP9 and osteopontin (OPN) levels, thereby reducing the risk of disease 
progression and/or metastasis. Dashed arrows indicate immune cell mobilisation.    






Unexpectedly, 1 mouse in the lyo LGG group was diagnosed with pyelonephritis 
and presented with kidney-to-liver adhesion; nonetheless the mouse was cured of bladder 
tumour (free-PSA negative) at the time of disease discovery. Lactobacillus translocation 
is a rare phenomenon and its clinical significance is poorly defined [196]. In the majority 
of the incidences reported, the patients had severe or fatal co-morbidities. Besides this, 
the predisposing factors to bacteria septicaemia include severe immunosuppression, prior 
prolong hospitalisation, surgical intervention, as well as the use of a wide range of broad-
spectrum antibiotics [197]. Furthermore, this was a one-off casualty in a sample 
population of 91 mice. It is thus maintained that lyo LGG instillations are safe for use.  
 
4.6 Effects of LGG in a healthy versus diseased bladder  
The fact that Lactobacillus species selectively mediate cytotoxicity is not 
unknown. Fischera and Giese observed that L. casei and its peptidoglycan elicited no 
toxic activity on normal human fibroblasts whilst having a stimulatory effect on 
lymphocytes. Yet the same bacteria and peptidoglycan preparations were found to be 
cytotoxic against a number of tumour cell lines [176]. The same phenomenon was 
reported by Ralph and Nakoinz on BCG and some macrophage-activating substances 
[198]. The disparity was believed to be due to the differential expressions of specific 
receptors for the immunostimulants – tumour cells being more sensitive than normal cells 
[198].  
Having compared the gene expression modulation and specific immune cell 
population changes between a healthy bladder and a diseased one, it also appears that 
LGG influenced these parameters categorically depending on the pathological states of 
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the bladder and the health of the host. The chief aim of studying these specific changes in 
a healthy bladder was to provide some indication as to how LGG might mediate its anti-
tumour mechanisms. Even though the immune responses in the healthy bladder did not 
directly reflect that of a tumour-bearing one, it nevertheless provided valuable data on the 
safety of LGG as an intravesical therapeutic. Besides this, the observation that repeated 
LGG instillations had chemoattractive potential even in a healthy bladder subsequently 
led to the discovery that like both LcS and BCG, LGG was able to assert its anti-tumour 
effects via neutrophils and macrophages.  
4.7 LGG’s direct killing mechanisms  
The fundamental goal of cancer research is to identify therapies that induce 
selective cancer cell death. Hence after verifying the immunomodulatory and anti-tumour 
properties of LGG, the final aim was to assess the efficacy of live and lyo LGG on cell 
growth, cell cycle progression and cell death. Using CalceinAM staining, it was found 
that LGG inhibited cell proliferation in vitro from as early as 48 hr in culture. Further to 
this, analysis using propidium iodide (PI) staining also showed that both live and lyo 
LGG, but not heat-killed LGG were able to induce an accumulation of cells in the sub-G1 
phase of cell cycle arrest, which was indicative of apoptosis and/ or necrosis (PI staining 
does not differentiate between the 2). The accumulation of cells in the sub-G1 phase was 
gradual from 24 hr and peaking at 72 hr. At the same time, there was a reduction in cell 
numbers in the treated wells.  
Collectively, these results indicated that LGG viability was essential to anti-
tumour activities, and cytotoxicity was elicited in a time-dependent possibly due to an 
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accumulation of the cytotoxic metabolite. It was also established that LGG did not 
require direct physical contact with the cancer cells in order to initiate killing, since 
killing occurred even in the presence of a cell culture insert which segregating the 
bacteria from mammalian cells. This data also provided evidence of a soluble cytotoxic 
product and corroborated with earlier data [95] where spent supernatants from human 
bladder cancer cells co-incubated with LGG could be transferred to another human 
bladder cancer cell line and still elicited the same cytotoxic effects.  
Since 72 hr appeared to be the optimum time for LGG’s cytotoxicity, further 
analysis was performed on the treated cells to elucidate the likely pathway via which 
killing was mediated. Particular attention was paid to nonsteroidal anti-inflammatory 
drugs activated gene 1 whose upregulation has been reported to possess antitumourigenic 
and proapoptotic activities in vitro and in vivo. Using quantitative PCR, it was found that 
MGH cells did not constitutively express high levels of NAG-1, but expression could be 
induced by both live and lyo LGG in a time-dependent manner, with mRNA levels 
peaking at 72 hr after incubation. It was also at 72 hr that the largest sub-G1 population 
(PI cell cycle analysis data) was found in MGH cells co-cultured with LGG, suggesting 
that the number apoptotic and/or necrotic cells was directly proportional to NAG-1 
mRNA upregulation.  
While NAG-1 upregulation is tightly associated with apoptosis, electron 
micrographs of 72 hr MGH cells treated with LGG (live and lyo) did not detect the 
distinct DNA fragmentation nor chromosomal condensation distinctive of apoptotic death 
[119]. Neither could caspase-3 activity be detected in proteins isolated from the 72 hr 
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treated cells. The lack of apoptotic cells suggested that there were other contributory 
pathways in its growth inhibitory responses in this human bladder TCC type.  
What was consistently observed in the electron micrographs though, were highly 
stressed LGG-treated humand bladder cancer cells which exhibited a moth-eaten 
appearance with multiple unstained areas and many lipid deposits; degradation of nucleus 
and other organelles were also evident, all of which were characteristic of necrotic cells 
[119]. To date, there are no reports of NAG-1’s role in necrosis, thus the relationship 
between NAG-1 and LGG-induced cell death could not be delineated here.  
Although there is insufficient definitive evidence to suggest that LGG induced 
necrosis, there was no doubt the treated cancer cells were unhealthy and invariably 
appeared rounded and detached from the culture wells from as early as 48 hr. More work 
needs to be done to distinguish the type of cell death LGG induced since each form of 
cell death has its therapeutic potentials. Understanding the processes and the type of cell 
death will allow the development of more targeted therapies and hence an augmentation 
of LGG anti-tumour efficacy. 
 
4.8 Lactic acid is not the cytotoxic metabolite 
Consistent with in vivo and splenocyte studies earlier, lyophilised LGG was 
consistently more effective than live LGG in impeding cell proliferation, resulting in a 
bigger population of dying cells (sub-G1 cell population), and inducing more copies of 
NAG-1. This was likely because lyophilised LGG preparations contain more cytotoxic 
metabolites. In addition to the de novo metabolites, other intracelullar cytotoxic 
compounds might have been released as a result of lyophilisation thereby increasing its 
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potency. Live LGG on the other hand, needed time to synthesize and amass the de novo 
cytotoxic metabolite before the threshold when cells start to die. It may also be pointed 
out that although lactic acid is the largest metabolic by-product (in terms of quantity) of 
Lactobacillus species it was not the cytotoxic metabolite-of-interest since the pH in 
control and LGG treated wells were comparable - control: pH 7.02, live LGG: pH 6.8, 
lyo LGG: pH 6.8.  
 
4.9 Translating in vitro evidence to in vivo tumour models 
Using the orthotopic animal bladder cancer model, it was been shown that LGG 
could elicit anti-tumour mechanisms indirectly, via the recruitment of immune cells, 
primarily neutrophils and macrophages. It was also demonstrated in vitro that LGG could 
be directly cytotoxic to bladder cancer cells. While the 2 may be distinctively different 
systems of studying LGG’s potential as a cancer immunotherapeutic, it is nevertheless 
indicative of LGG’s role for direct cytotoixc effects in vivo – when instilled in the 
bladder, LGG would be in close proximity to the bladder cancer cells if not already in 
direct contact with them. As such the in vitro cytotoxicity observed can be extrapolated to 









Despite LGG’s long history of use as probiotics and in the production of 
fermented milk products, it has been shown convincingly for the first time that 6 weekly 
intravesical LGG instillations are equally efficacious as the current gold standard, BCG. 
Like LcS, LGG instillations were able to confer survival advantage and significant 
protective effects over PBS controls. LGG’s anti-tumour effects could be observed within 
2 weeks of therapy yet with minimal side-effects, whereas BCG therapy is known to 
require at least four consecutive instillations before a significant response could be 
observed. By optimising LGG instillation schedule, LGG may potentially be more 
effective than BCG as an adjuvant in superficial bladder cancer therapy.  
It was also established that lyophilisation augmented LGG’s immunodulatory 
capabilities enhancing its immunogenicity. Furthermore the results also clearly 
demonstrated the biological effects of LGG, a widely consumed dietary supplement, on 
human and murine bladder transitional carcinoma cells; LGG could also induce growth 
inhibition and cell death in both bladder cancer cells. The present study also partially 
elucidated the anti-tumour effects of LGG likely through the recruitment of neutrophils 
and macrophages.  
It is thus concluded that lyophilised LGG may be a safer alternative to BCG in 







4.11 Future directions 
 
It has been shown in this series of experiments that the immunotherapy of bladder 
tumours with Lactobacillus rhamnosus strain GG (LGG) preparations has been proven to 
be a success.  However, key metabolites and pathways responsible for the for LGG 
effectiveness are still not completely understood. As such further research should be 
aimed at the following: 
 
1. Understanding the type of cell death that LGG induces as this may be critical in 
enhancing LGG’s efficacy as a cancer therapeutic. Although apoptosis is largely 
immune silent or immunosuppressive, therapy-induced necrotic cell death 
initiates an immune response to tumour cells. The inflammation that ensue 
necrosis may be desirable or form fertile grounds for further tumour growth. 
Ascertaining this will allow the eventual manipulation for therapeutic benefit. 
Future experiments should be centred on confirming the lack of caspase activities 
to definitely rule out apoptosis. Tests should also be conducted to detect lactate 
dehydrogenase, one of the key necrosis indicators and the leakage of this enzyme 
into extracellular supernatant has often been used as a marker of necrotic cell 
death. The measurement of extracellular lactate dehydrogenase has been a 
promising approach to define necrotic cell death in vitro and can be performed 




2. Identifying the major anti-tumour metabolite(s) of LGG. Since there is some 
evidence that the LGG anti-tumour and cytotoxic metabolite may be a protein that 
is synthesised only when LGG is in close proximity to the cancer cells. Future 
work can first focus on determining the size of the metabolic protein with by 
experimenting with various spin columns that allows the crude separation of 
proteins based on their molecular weights. With success, the process of high-
performance liquid chromatography and mass spectrometry can follow to classify 
the protein. The eventual focus after identifying the cytotoxic protein should 
revolve around the stability of the protein and the specific environment in which 
the protein induces death. Pinpointing this may circumvent the need to instil live 
bacteria.  
3. Aside from the in vitro studies, it would also be imperative to ascertain the anti-
tumour efficacy when LGG is administered singularly via the oral route. The 
reason is because the type and stage of the cancer as well as the physical 
condition of the patient may directly influence the success of instillation. The 
failure to successfully instill LGG may disrupt and compromise its efficacy. On 
the other hand, oral therapy is less invasive and intimidating for the patient. Most 
of the clinical data with LcS were also derived from delivering it as an oral 
preparation, as such it may be worthwhile exploring LGG as an oral therapeutic. 
For a start, oral LGG can be administered everyday on its own, or in addition to 
intravesical BCG therapy, after orthotopic tumour implantation to determine the 
efficacy of oral LGG therapy. Since the regular consumption of LGG is not 
known to have deleterious effects on the host, the proposed oral LGG therapy is 
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thus highly feasible. Since continuing efforts to create supportive efficacy and 
safety data will enhance credibility and acceptance of probiotics by both 
physicians as well as consumers, in vivo studies on changes to the immune 
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